⚙

Pathophysiology

6

Complex Genetic Liability

Tourette syndrome has familial clustering and complex genetic architecture involving common, rare, and structural variant contributions rather than a single-gene etiology for most cases.

Downstream

Structural Variant Effects on Synaptic Processes Rare and structural variants in multiplex families are modeled as one genetic route into synaptic and neurodevelopmental process disruption.

Neurodevelopmental Migration and Neurite Outgrowth Effects Genetic liability is modeled upstream of neuronal migration and neurite outgrowth pathways implicated by enrichment analyses.

Show evidence (4 references)

DOI:10.3390/brainsci15050426 SUPPORT Human Clinical

"Tourette syndrome (TS) is a neurodevelopmental disorder, manifested by tics and a variety of behavioral comorbidities that cluster strongly within families, suggesting a combination of genetic and environmental risk factors."

Review evidence supports familial clustering and mixed genetic and environmental risk.

PMID:8708658 SUPPORT Human Clinical

"In 84% of patients there was a family"

Brazilian cohort data supports strong familial clustering of tics in TS.

PMID:33634279 SUPPORT Human Clinical

"Genetic factors play an important part in the aetiology of GTS, and"

Review confirms genetic factors and familial expression of tics and related disorders.

+ 1 more reference

Structural Variant Effects on Synaptic Processes

Familial whole-genome sequencing identifies rare structural variants whose candidate gene sets are enriched for synaptic vesicle endocytosis and neurotransmission-related processes.

synaptic vesicle endocytosis link ⚠ ABNORMAL chemical synaptic transmission link ⚠ ABNORMAL

Downstream

Cortico-Striato-Thalamo-Cortical Circuit Dysregulation Synaptic process disruption is modeled upstream of circuit-level dysregulation in tic-generation pathways.

Show evidence (2 references)

DOI:10.3390/ijms25115758 SUPPORT Human Clinical

"Seventy putative pathogenic variants shared among affected individuals within one family but not present in the control group were identified."

Familial WGS identifies candidate structural variants segregating with TS in multiplex families.

DOI:10.3390/ijms25115758 SUPPORT Human Clinical

"Enrichment analysis showed that identified structural variants affected synaptic vesicle endocytosis, cell leading-edge organization, and signaling for neurite outgrowth."

This directly supports a synaptic-vesicle mechanism node.

Neurodevelopmental Migration and Neurite Outgrowth Effects

Structural variant enrichment implicates neuronal migration and neurite outgrowth pathways, suggesting developmental effects on circuit assembly.

neuron link

neuron migration link ⚠ ABNORMAL

Downstream

Cortico-Striato-Thalamo-Cortical Circuit Dysregulation Altered neuronal migration and outgrowth are represented as upstream developmental contributors to CSTC circuit vulnerability.

Show evidence (1 reference)

DOI:10.3390/ijms25115758 SUPPORT Human Clinical

"The results further support the involvement of the regulation of neurotransmission, neuronal migration, and sound-sensing in GTS."

Structural-variant pathway analysis supports neuronal migration as an implicated process in familial TS.

Cortico-Striato-Thalamo-Cortical Circuit Dysregulation

Tourette syndrome is modeled as involving abnormal regulation across cortical, striatal, and thalamic circuit nodes that participate in motor selection and tic suppression.

medium spiny neuron link GABAergic interneuron link

modulation of chemical synaptic transmission link ⚠ ABNORMAL

prefrontal cortex link striatum link dorsal plus ventral thalamus link

Downstream

Dopamine-Modulated Tic Circuit Output Circuit dysregulation is modeled upstream of neurotransmitter-modulated motor and phonic tic output.

Show evidence (2 references)

PMID:29986411 SUPPORT Human Clinical

"In the pathophysiology of TS, cortico-striatal-thalamo-cortical circuits (CSTC) connecting brain cortical regions to basal ganglia, are critical to its presumed pathophysiology"

Review directly identifies CSTC circuits connecting cortex to basal ganglia as central to presumed TS pathophysiology.

DOI:10.1007/s00787-021-01899-z PARTIAL Other

"The largest amount of evidence supports the use of dopamine blocking agents, preferably aripiprazole because of a more favorable profile of adverse events than first- and second-generation antipsychotics."

Pharmacologic evidence supports dopamine-sensitive tic circuitry, though the abstract does not directly localize the full CSTC circuit.

Dopamine-Modulated Tic Circuit Output

Dopamine-sensitive neurotransmission is represented as a proximal modulator of motor and vocal tic expression, based on evidence for dopamine-blocking medication efficacy.

modulation of chemical synaptic transmission link ⚠ ABNORMAL

striatum link

Downstream

Motor and Vocal Tics Altered neurotransmitter modulation of tic circuits produces recurrent motor and phonic tic behaviors.

Show evidence (1 reference)

DOI:10.1007/s00787-021-01899-z PARTIAL Human Clinical

"The largest amount of evidence supports the use of dopamine blocking agents, preferably aripiprazole because of a more favorable profile of adverse events than first- and second-generation antipsychotics."

Dopamine-blocking treatment efficacy supports dopamine-sensitive tic circuit output, but this is indirect mechanistic evidence.

Peripheral Immune and Biomarker Alterations

Peripheral immune, metabolic, and neurotrophic biomarkers differ between TS and control groups in meta-analysis, but larger standardized studies are needed before diagnostic use.

inflammatory response link ⚠ ABNORMAL

Downstream

Cortico-Striato-Thalamo-Cortical Circuit Dysregulation Peripheral biomarker changes are represented as associated with TS biology but not as proven causal drivers of CSTC dysfunction.

Show evidence (2 references)

DOI:10.3389/fneur.2024.1262057 SUPPORT Human Clinical

"A total of 81 studies were identified, out of which 60 met the eligibility criteria for inclusion in the meta-analysis."

Biomarker meta-analysis provides broad evidence for peripheral marker differences in TS.

DOI:10.3389/fneur.2024.1262057 SUPPORT Human Clinical

"13 comparisons were statistically significant [CD3+ T cell, CD4+ T cell, CD4+ T cell to CD8+ T cell ratio, NK-cell, anti-streptolysin O antibodies, anti-DNase antibodies, glutamic acid (Glu), aspartic acid (Asp), ferritin (Fe), zinc (Zn), lead (Pb), vitamin D, and brain-derived neurotrophic..."

The statistically significant comparisons support a peripheral biomarker alteration node while retaining diagnostic caution.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Nervous System 5

Attention Deficit Hyperactivity Disorder FREQUENT Attention deficit hyperactivity disorder (HP:0007018)

Show evidence (3 references)

PMID:22411257 SUPPORT Human Clinical

"comorbid neuropsychiatric disorders occur in approximately 90% of patients, with attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) being the most common ones."

Review confirms ADHD as one of the two most common TS comorbidities.

PMID:8708658 SUPPORT Human Clinical

"Attention deficit and hyperactivity disorder was diagnosed in 63%"

Brazilian cohort provides quantitative prevalence of ADHD in TS patients.

PMID:24295616 SUPPORT Human Clinical

"the presence of comorbid attention deficit hyperactivity disorder (ADHD) is the main determinant of cognitive dysfunction in TS patients and influences heavily also the risk of developing disruptive"

Identifies ADHD as primary driver of cognitive dysfunction in TS.

Anxiety Anxiety (HP:0000739)

Show evidence (1 reference)

DOI:10.1186/s13052-023-01562-0 SUPPORT Human Clinical

"the total estimate of the prevalence of depression and anxiety in patients with TS was 36.4%"

Meta-analysis supports anxiety as a common TS comorbidity.

Depression Depression (HP:0000716)

Show evidence (2 references)

DOI:10.1186/s13052-023-01562-0 SUPPORT Human Clinical

"The results of the present study showed that the prevalence of depression and anxiety was high in patients with TS."

Meta-analysis supports depression as a frequent comorbidity in TS.

PMID:22411257 SUPPORT Human Clinical

"a high prevalence of depression and personality disorders has been reported."

Review confirms high prevalence of depression in TS.

Obsessive-Compulsive Behavior Compulsive behaviors (HP:0000722)

Show evidence (2 references)

PMID:24295616 SUPPORT Human Clinical

"Obsessive-compulsive symptoms and related disorder (OCD) are common in TS, and the clinical distinction between compulsions and complex tics may be difficult in some cases."

Comprehensive phenomenology review supports OCD as common TS comorbidity.

PMID:8708658 SUPPORT Human Clinical

"compulsive behaviour in 44% of patients"

Brazilian cohort quantifies OCD prevalence at 44% of TS patients.

Sleep Disturbance Sleep disturbance (HP:0002360)

Show evidence (2 references)

PMID:32554211 SUPPORT Human Clinical

"Sleep disorders are very common in patients diagnosed with Tourette syndrome"

Systematic review confirms high prevalence of sleep disorders in TS.

PMID:32554211 SUPPORT Human Clinical

"Insomnia, excessive daytime sleepiness, disorders of arousal (sleepwalking, sleeptalking, sleep terrors, and enuresis), the persistence of tics during sleep, and presence of periodic limb movements during sleep (PLMS) were very frequent in patients with TS."

Specifies the types of sleep disturbances common in TS.

Other 5

Motor and Vocal Tics Tics (HP:0100033)

Show evidence (2 references)

PMID:24295616 SUPPORT Human Clinical

"Motor and phonic tics are the core features of"

Comprehensive phenomenology review confirms motor and phonic tics as core defining features of TS.

PMID:22411257 SUPPORT Human Clinical

"Tourette syndrome (TS) is a neurodevelopmental disorder consisting of multiple"

Review confirms the defining motor-plus-vocal tic criterion.

Motor Tics Tics (HP:0100033)

Show evidence (1 reference)

PMID:8708658 SUPPORT Human Clinical

"Blinking, grimacing, and shoulder elevation were the most common motor tics"

Brazilian cohort study documents the most common motor tic types.

Vocal Tics Tics (HP:0100033)

Show evidence (1 reference)

PMID:8708658 SUPPORT Human Clinical

"sniffing, throat clearing, and grunting noises, the most frequent vocal tics."

Brazilian cohort study documents the most frequent vocal tic types.

Coprolalia OCCASIONAL Tics (HP:0100033)

Show evidence (2 references)

PMID:19183216 SUPPORT Human Clinical

"Coprolalia occurred at some point in the lifetime of 19.3% of males and 14.6% of females"

International consortium data quantifies coprolalia prevalence in TS.

PMID:19183216 SUPPORT Human Clinical

"emergence occurs in only about one in five referred patients."

Confirms coprolalia as a minority feature rather than universal in TS.

Premonitory Sensory Urges

Show evidence (1 reference)

PMID:24295616 SUPPORT Human Clinical

"The sensory phenomena of TS are increasingly recognized as another crucial symptom of TS and consist of premonitory urges and somatic hypersensitivity."

Comprehensive phenomenology review identifies sensory phenomena as a crucial TS symptom domain.

🧬

Genetic Associations

3

HDC (Rare pathogenic variant in familial Tourette syndrome)

Show evidence (1 reference)

PMID:24411733 SUPPORT Human Clinical

"has been implicated as a rare genetic cause."

Familial genetics review identifies HDC as one of the two currently recognized rare pathogenic single-variant genes for GTS.

SLITRK1 (Rare pathogenic variant in familial Tourette syndrome)

Show evidence (1 reference)

PMID:16224024 SUPPORT Human Clinical

"these findings support the association of rare SLITRK1 sequence variants with"

Familial genetics review identifies SLITRK1 as one of the two currently recognized rare pathogenic single-variant genes for GTS.

Polygenic genetic liability (Complex multifactorial and polygenic susceptibility)

Show evidence (2 references)

DOI:10.3390/brainsci15050426 SUPPORT Human Clinical

"Tourette syndrome (TS) is a neurodevelopmental disorder, manifested by tics and a variety of behavioral comorbidities that cluster strongly within families, suggesting a combination of genetic and environmental risk factors."

Epidemiology review supports familial clustering and a combined genetic and environmental liability model.

DOI:10.3390/ijms25115758 SUPPORT Human Clinical

"complex and elusive etiology with a significant role of genetic factors"

Structural-variant review supports the interpretation that most GTS is genetically heterogeneous rather than explained by a single gene.

💊

Treatments

3

Behavioral therapy for tics

Action: cognitive behavior therapy MAXO:0000883

Psychoeducation and behavioral approaches, including CBIT, habit-reversal training, and exposure-response prevention, are preferred first-line nonpharmacologic treatments when available and feasible.

Target Phenotypes: Tics ↗

Show evidence (1 reference)

DOI:10.1007/s00787-021-01899-z SUPPORT Other

"The first preference should be given to psychoeducation and to behavioral approaches, as it strengthens the patients’ self-regulatory control and thus his/her autonomy."

ESSTS guideline abstract supports psychoeducation and behavioral approaches as preferred first-line management for TS.

Dopamine-blocking pharmacotherapy

Action: Pharmacotherapy NCIT:C15986

Agent: aripiprazole ↗

Dopamine-blocking pharmacotherapy, preferably aripiprazole, is used when behavioral approaches are ineffective, unavailable, or infeasible.

Mechanism Target:

MODULATES Dopamine-Modulated Tic Circuit Output — Dopamine-blocking agents are modeled as modulating dopamine-sensitive tic circuit output.

Target Phenotypes: Tics ↗

Show evidence (1 reference)

DOI:10.1007/s00787-021-01899-z SUPPORT Other

"The largest amount of evidence supports the use of dopamine blocking agents, preferably aripiprazole because of a more favorable profile of adverse events than first- and second-generation antipsychotics."

Guideline evidence supports dopamine-blocking agents, with aripiprazole preferred because of adverse-event profile.

Alpha-2 agonist pharmacotherapy for ADHD comorbidity

Action: Pharmacotherapy NCIT:C15986

Agent: clonidine ↗ guanfacine ↗

Clonidine and guanfacine can be considered when Tourette syndrome coexists with attention deficit hyperactivity disorder.

Target Phenotypes: Tics ↗

Show evidence (1 reference)

DOI:10.1007/s00787-021-01899-z SUPPORT Other

"Other agents that can be considered include tiapride, risperidone, and especially in case of co-existing attention deficit hyperactivity disorder (ADHD), clonidine and guanfacine."

Guideline evidence supports clonidine and guanfacine consideration in TS with co-existing ADHD.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Tourette Syndrome:

Functional tic-like movement disorder

Overlapping Features Functional tic-like movements can resemble primary tics but often have atypical onset, suppressibility, and treatment-response patterns.

Show evidence (1 reference)

DOI:10.1007/s00787-021-01842-2 SUPPORT Other

"new information has been added regarding differential diagnoses, with an emphasis on functional movement disorders in both children and adults."

ESSTS guideline highlights functional movement disorders in tic-disorder differential diagnosis.

Stereotypic movement disorder Not Yet Curated MONDO:0002265

Overlapping Features Stereotypies can be mistaken for tics and require distinction by phenomenology, age at onset, rhythm, and suppressibility.

Show evidence (1 reference)

DOI:10.1007/s00787-021-01842-2 PARTIAL Other

"assessments supporting the differential diagnosis process are given as well as tests to analyse cognitive abilities, emotional functions and motor skills."

The abstract supports motor-skill and differential-diagnosis assessment, though it does not name stereotypic movement disorder.

Tic disorder Not Yet Curated MONDO:0002420

Overlapping Features Other tic disorders can share motor or vocal tics but do not necessarily meet full Tourette syndrome duration and motor-plus-vocal criteria.

Show evidence (1 reference)

DOI:10.1007/s00787-021-01842-2 SUPPORT Other

"Now, we present an updated version 2.0 of these European clinical guidelines for Tourette syndrome and other tic disorders, part I: assessment."

The guideline scope supports distinguishing Tourette syndrome from other tic disorders.

Obsessive-compulsive disorder Not Yet Curated MONDO:0008114

Overlapping Features OCD frequently co-occurs with TS and can dominate impairment, but compulsions are distinguished from tics by phenomenology and intent.

Show evidence (1 reference)

DOI:10.1007/s00787-021-01842-2 PARTIAL Other

"Recommendations are provided for scales for the assessment of tics and psychiatric comorbidities in patients with TS not only in routine clinical practice, but also in the context of clinical research."

The guideline supports psychiatric comorbidity assessment; OCD-specific distinction is inferred from TS clinical practice and HPO phenotype mapping.

📊

Related Datasets

2

Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome DOI:10.3390/ijms25115758

Familial whole-genome sequencing dataset of 17 multiplex families with 80 TS patients, used to identify structural variants and enriched biological processes.

Homo sapiens n=80

Conditions: familial Tourette syndrome structural variants

Findings

Familial TS structural variants were enriched for synaptic vesicle endocytosis and neurite outgrowth signaling.

Show evidence (1 reference)

DOI:10.3390/ijms25115758 SUPPORT Human Clinical

"Enrichment analysis showed that identified structural variants affected synaptic vesicle endocytosis, cell leading-edge organization, and signaling for neurite outgrowth."

Captures the principal pathway-enrichment finding from the dataset.

DOI:10.3390/ijms25115758

Show evidence (1 reference)

DOI:10.3390/ijms25115758 SUPPORT Human Clinical

"The study group comprised 17 multiplex families with 80 patients."

The abstract describes the human familial WGS cohort.

Biomarkers and Tourette syndrome: a systematic review and meta-analysis DOI:10.3389/fneur.2024.1262057

Systematic-review and meta-analysis dataset of peripheral biomarkers in TS case-control studies.

Homo sapiens

Conditions: Tourette syndrome control

Findings

Multiple immune, amino-acid, mineral, and neurotrophic markers differed between TS and controls.

Show evidence (1 reference)

DOI:10.3389/fneur.2024.1262057 SUPPORT Human Clinical

"13 comparisons were statistically significant [CD3+ T cell, CD4+ T cell, CD4+ T cell to CD8+ T cell ratio, NK-cell, anti-streptolysin O antibodies, anti-DNase antibodies, glutamic acid (Glu), aspartic acid (Asp), ferritin (Fe), zinc (Zn), lead (Pb), vitamin D, and brain-derived neurotrophic..."

Captures the meta-analysis finding of statistically significant biomarker differences.

DOI:10.3389/fneur.2024.1262057

Show evidence (1 reference)

DOI:10.3389/fneur.2024.1262057 SUPPORT Human Clinical

"A total of 81 studies were identified, out of which 60 met the eligibility criteria for inclusion in the meta-analysis."

The abstract describes the evidence base for the biomarker meta-analysis.

🔬

Clinical Trials

3

NCT04007991 PHASE_II COMPLETED

Phase 2b randomized placebo-controlled study of ecopipam tablets in children and adolescents with Tourette syndrome.

Target Phenotypes: Tics ↗

Show evidence (1 reference)

clinicaltrials:NCT04007991 SUPPORT

"This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS)."

ClinicalTrials.gov record documents a pediatric ecopipam trial targeting TS.

NCT05615220 PHASE_III COMPLETED

Phase 3 multicenter randomized-withdrawal study evaluating maintenance of ecopipam efficacy, safety, and tolerability in Tourette disorder.

Target Phenotypes: Tics ↗

Show evidence (1 reference)

clinicaltrials:NCT05615220 SUPPORT

"This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD)."

ClinicalTrials.gov record documents a late-stage ecopipam trial in TD.

NCT02674321 PHASE_I COMPLETED

Pilot study of SD-809/deutetrabenazine for moderate to severe Tourette syndrome.

Target Phenotypes: Tics ↗

Show evidence (1 reference)

clinicaltrials:NCT02674321 SUPPORT

"The purpose of this study is to evaluate safety, tolerability and preliminary efficacy of SD-809 in the treatment of motor and phonic tics of Tourette Syndrome and to evaluate the pharmacokinetic of SD-809 and its metabolites."

ClinicalTrials.gov record documents deutetrabenazine testing for motor and phonic tics.

{ }

Source YAML

click to show

name: Tourette Syndrome
creation_date: "2026-04-24T20:56:38Z"
updated_date: "2026-05-02T00:00:00Z"
category: Psychiatric
description: >-
  Tourette syndrome is a childhood-onset neurodevelopmental tic disorder
  characterized by multiple motor tics and at least one vocal tic persisting
  for more than one year.
disease_term:
  preferred_term: Tourette syndrome
  term:
    id: MONDO:0007661
    label: Tourette syndrome
parents:
- Neurodevelopmental Disorder
- Mental Health Disorder
prevalence:
- population: children and adolescents
  percentage: 1
  notes: >-
    Review estimate for TS prevalence in children and adolescents; adult
    prevalence is much lower.
  evidence:
  - reference: DOI:10.3390/brainsci15050426
    reference_title: Epidemiology of Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence of TS is estimated to be about 1% in children and
      adolescents and approximately 0.01% in adults, with a male-to-female
      (M:F) ratio of about 4:1.
    explanation: >-
      Epidemiology review provides age-stratified prevalence and sex-ratio
      estimates.
  - reference: PMID:24295616
    reference_title: An introduction to the clinical phenomenology of Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an estimated prevalence close to 1%"
    explanation: >-
      Phenomenology review confirms approximately 1% prevalence in the
      pediatric age range.
  - reference: PMID:33634279
    reference_title: Tourette syndrome in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "vocal tics, has a prevalence of approximately 1%"
    explanation: >-
      Review confirms 1% prevalence estimate in school-aged children.
pathophysiology:
- name: Complex Genetic Liability
  description: >-
    Tourette syndrome has familial clustering and complex genetic architecture
    involving common, rare, and structural variant contributions rather than a
    single-gene etiology for most cases.
  downstream:
  - target: Structural Variant Effects on Synaptic Processes
    description: >-
      Rare and structural variants in multiplex families are modeled as one
      genetic route into synaptic and neurodevelopmental process disruption.
  - target: Neurodevelopmental Migration and Neurite Outgrowth Effects
    description: >-
      Genetic liability is modeled upstream of neuronal migration and neurite
      outgrowth pathways implicated by enrichment analyses.
  evidence:
  - reference: DOI:10.3390/brainsci15050426
    reference_title: Epidemiology of Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tourette syndrome (TS) is a neurodevelopmental disorder, manifested by
      tics and a variety of behavioral comorbidities that cluster strongly
      within families, suggesting a combination of genetic and environmental
      risk factors.
    explanation: >-
      Review evidence supports familial clustering and mixed genetic and
      environmental risk.
  - reference: PMID:8708658
    reference_title: A Brazilian cohort of patients with Tourette's syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 84% of patients there was a family"
    explanation: >-
      Brazilian cohort data supports strong familial clustering of tics in TS.
  - reference: PMID:33634279
    reference_title: Tourette syndrome in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic factors play an important part in the aetiology of GTS, and"
    explanation: >-
      Review confirms genetic factors and familial expression of tics and
      related disorders.
  - reference: DOI:10.3390/ijms25115758
    reference_title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gilles de la Tourette syndrome (GTS) is a neurodevelopmental psychiatric
      disorder with complex and elusive etiology with a significant role of
      genetic factors.
    explanation: >-
      Familial WGS study frames TS as genetically influenced and etiologically
      complex.
- name: Structural Variant Effects on Synaptic Processes
  description: >-
    Familial whole-genome sequencing identifies rare structural variants whose
    candidate gene sets are enriched for synaptic vesicle endocytosis and
    neurotransmission-related processes.
  biological_processes:
  - preferred_term: synaptic vesicle endocytosis
    term:
      id: GO:0048488
      label: synaptic vesicle endocytosis
    modifier: ABNORMAL
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: ABNORMAL
  downstream:
  - target: Cortico-Striato-Thalamo-Cortical Circuit Dysregulation
    description: >-
      Synaptic process disruption is modeled upstream of circuit-level
      dysregulation in tic-generation pathways.
    evidence:
    - reference: DOI:10.3390/ijms25115758
      reference_title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The results further support the involvement of the regulation of
        neurotransmission, neuronal migration, and sound-sensing in GTS.
      explanation: >-
        Enrichment results connect familial structural variants with
        neurotransmission and neuronal migration processes relevant to circuit
        dysfunction.
  evidence:
  - reference: DOI:10.3390/ijms25115758
    reference_title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seventy putative pathogenic variants shared among affected individuals
      within one family but not present in the control group were identified.
    explanation: >-
      Familial WGS identifies candidate structural variants segregating with TS
      in multiplex families.
  - reference: DOI:10.3390/ijms25115758
    reference_title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Enrichment analysis showed that identified structural variants affected
      synaptic vesicle endocytosis, cell leading-edge organization, and
      signaling for neurite outgrowth.
    explanation: >-
      This directly supports a synaptic-vesicle mechanism node.
- name: Neurodevelopmental Migration and Neurite Outgrowth Effects
  description: >-
    Structural variant enrichment implicates neuronal migration and neurite
    outgrowth pathways, suggesting developmental effects on circuit assembly.
  biological_processes:
  - preferred_term: neuron migration
    term:
      id: GO:0001764
      label: neuron migration
    modifier: ABNORMAL
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Cortico-Striato-Thalamo-Cortical Circuit Dysregulation
    description: >-
      Altered neuronal migration and outgrowth are represented as upstream
      developmental contributors to CSTC circuit vulnerability.
  evidence:
  - reference: DOI:10.3390/ijms25115758
    reference_title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results further support the involvement of the regulation of
      neurotransmission, neuronal migration, and sound-sensing in GTS.
    explanation: >-
      Structural-variant pathway analysis supports neuronal migration as an
      implicated process in familial TS.
- name: Cortico-Striato-Thalamo-Cortical Circuit Dysregulation
  description: >-
    Tourette syndrome is modeled as involving abnormal regulation across
    cortical, striatal, and thalamic circuit nodes that participate in motor
    selection and tic suppression.
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: GABAergic interneuron
    term:
      id: CL:0011005
      label: GABAergic interneuron
  biological_processes:
  - preferred_term: modulation of chemical synaptic transmission
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
    modifier: ABNORMAL
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: dorsal plus ventral thalamus
    term:
      id: UBERON:0001897
      label: dorsal plus ventral thalamus
  downstream:
  - target: Dopamine-Modulated Tic Circuit Output
    description: >-
      Circuit dysregulation is modeled upstream of neurotransmitter-modulated
      motor and phonic tic output.
  evidence:
  - reference: PMID:29986411
    reference_title: "Transcranial Magnetic Stimulation in Tourette Syndrome: A Historical Perspective, Its Current Use and the Influence of Comorbidities in Treatment Response."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the pathophysiology of TS, cortico-striatal-thalamo-cortical circuits
      (CSTC) connecting brain cortical regions to basal ganglia, are critical
      to its presumed pathophysiology
    explanation: >-
      Review directly identifies CSTC circuits connecting cortex to basal
      ganglia as central to presumed TS pathophysiology.
  - reference: DOI:10.1007/s00787-021-01899-z
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      The largest amount of evidence supports the use of dopamine blocking
      agents, preferably aripiprazole because of a more favorable profile of
      adverse events than first- and second-generation antipsychotics.
    explanation: >-
      Pharmacologic evidence supports dopamine-sensitive tic circuitry, though
      the abstract does not directly localize the full CSTC circuit.
- name: Dopamine-Modulated Tic Circuit Output
  description: >-
    Dopamine-sensitive neurotransmission is represented as a proximal modulator
    of motor and vocal tic expression, based on evidence for dopamine-blocking
    medication efficacy.
  biological_processes:
  - preferred_term: modulation of chemical synaptic transmission
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
    modifier: ABNORMAL
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  downstream:
  - target: Motor and Vocal Tics
    description: >-
      Altered neurotransmitter modulation of tic circuits produces recurrent
      motor and phonic tic behaviors.
    evidence:
    - reference: DOI:10.1186/s13052-023-01562-0
      reference_title: "Prevalence of depression and anxiety in patients with Tourette syndrome; 1997 to 2022: a systematic review and meta-analysis"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Tourette Syndrome (TS) is a disorder in which the patient has a history
        of multiple motor and vocal tics.
      explanation: >-
        Defines the downstream clinical tic phenotype.
  evidence:
  - reference: DOI:10.1007/s00787-021-01899-z
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The largest amount of evidence supports the use of dopamine blocking
      agents, preferably aripiprazole because of a more favorable profile of
      adverse events than first- and second-generation antipsychotics.
    explanation: >-
      Dopamine-blocking treatment efficacy supports dopamine-sensitive tic
      circuit output, but this is indirect mechanistic evidence.
- name: Peripheral Immune and Biomarker Alterations
  description: >-
    Peripheral immune, metabolic, and neurotrophic biomarkers differ between TS
    and control groups in meta-analysis, but larger standardized studies are
    needed before diagnostic use.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: ABNORMAL
  downstream:
  - target: Cortico-Striato-Thalamo-Cortical Circuit Dysregulation
    description: >-
      Peripheral biomarker changes are represented as associated with TS biology
      but not as proven causal drivers of CSTC dysfunction.
  evidence:
  - reference: DOI:10.3389/fneur.2024.1262057
    reference_title: "Biomarkers and Tourette syndrome: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 81 studies were identified, out of which 60 met the eligibility
      criteria for inclusion in the meta-analysis.
    explanation: >-
      Biomarker meta-analysis provides broad evidence for peripheral marker
      differences in TS.
  - reference: DOI:10.3389/fneur.2024.1262057
    reference_title: "Biomarkers and Tourette syndrome: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      13 comparisons were statistically significant [CD3+ T cell, CD4+ T cell,
      CD4+ T cell to CD8+ T cell ratio, NK-cell, anti-streptolysin O
      antibodies, anti-DNase antibodies, glutamic acid (Glu), aspartic acid
      (Asp), ferritin (Fe), zinc (Zn), lead (Pb), vitamin D, and brain-derived
      neurotrophic factor (BDNF)].
    explanation: >-
      The statistically significant comparisons support a peripheral biomarker
      alteration node while retaining diagnostic caution.
phenotypes:
- name: Motor and Vocal Tics
  category: Neurologic
  description: >-
    Multiple motor tics and at least one vocal or phonic tic define Tourette
    syndrome. Motor and phonic tics are the core features of TS, displaying a
    peculiar variability over time influenced by contextual factors.
  phenotype_term:
    preferred_term: Tics
    term:
      id: HP:0100033
      label: Tics
  diagnostic: true
  evidence:
  - reference: PMID:24295616
    reference_title: An introduction to the clinical phenomenology of Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Motor and phonic tics are the core features of"
    explanation: >-
      Comprehensive phenomenology review confirms motor and phonic tics as
      core defining features of TS.
  - reference: PMID:22411257
    reference_title: Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tourette syndrome (TS) is a neurodevelopmental disorder consisting of multiple"
    explanation: >-
      Review confirms the defining motor-plus-vocal tic criterion.
- name: Motor Tics
  category: Neurologic
  description: >-
    Motor tics are a required Tourette syndrome tic domain. Common motor tics
    include blinking, grimacing, and shoulder elevation.
  phenotype_term:
    preferred_term: Motor tics
    term:
      id: HP:0100033
      label: Tics
  diagnostic: true
  evidence:
  - reference: PMID:8708658
    reference_title: A Brazilian cohort of patients with Tourette's syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Blinking, grimacing, and shoulder
      elevation were the most common motor tics
    explanation: >-
      Brazilian cohort study documents the most common motor tic types.
- name: Vocal Tics
  category: Neurologic
  description: >-
    Vocal or phonic tics are a required Tourette syndrome tic domain. Common
    vocal tics include sniffing, throat clearing, and grunting noises.
  phenotype_term:
    preferred_term: Vocal tics
    term:
      id: HP:0100033
      label: Tics
  diagnostic: true
  evidence:
  - reference: PMID:8708658
    reference_title: A Brazilian cohort of patients with Tourette's syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      sniffing, throat clearing, and
      grunting noises, the most frequent vocal tics.
    explanation: >-
      Brazilian cohort study documents the most frequent vocal tic types.
- name: Coprolalia
  category: Behavioral
  description: >-
    Involuntary utterance of socially unacceptable words occurs in a minority
    of patients with Tourette syndrome. Coprolalia occurred in approximately
    19% of males and 15% of females in a large international database study.
  phenotype_term:
    preferred_term: Coprolalia
    term:
      id: HP:0100033
      label: Tics
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:19183216
    reference_title: Coprophenomena in Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Coprolalia occurred at some point in the lifetime of 19.3% of males
      and 14.6% of females
    explanation: >-
      International consortium data quantifies coprolalia prevalence in TS.
  - reference: PMID:19183216
    reference_title: Coprophenomena in Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "emergence occurs in only about one in five referred patients."
    explanation: >-
      Confirms coprolalia as a minority feature rather than universal in TS.
- name: Attention Deficit Hyperactivity Disorder
  category: Behavioral
  description: >-
    ADHD is the most common comorbid neuropsychiatric disorder in Tourette
    syndrome, present in roughly 60% or more of referred patients. Comorbid
    ADHD is the main determinant of cognitive dysfunction in TS patients.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  frequency: FREQUENT
  evidence:
  - reference: PMID:22411257
    reference_title: Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      comorbid neuropsychiatric disorders occur in approximately 90% of patients, with
      attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive
      disorder (OCD) being the most common ones.
    explanation: >-
      Review confirms ADHD as one of the two most common TS comorbidities.
  - reference: PMID:8708658
    reference_title: A Brazilian cohort of patients with Tourette's syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Attention
      deficit and hyperactivity disorder was diagnosed in 63%
    explanation: >-
      Brazilian cohort provides quantitative prevalence of ADHD in TS patients.
  - reference: PMID:24295616
    reference_title: An introduction to the clinical phenomenology of Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      the presence of comorbid attention deficit
      hyperactivity disorder (ADHD) is the main determinant of cognitive dysfunction
      in TS patients and influences heavily also the risk of developing disruptive
    explanation: >-
      Identifies ADHD as primary driver of cognitive dysfunction in TS.
- name: Anxiety
  category: Behavioral
  description: Anxiety is a common psychiatric comorbidity in TS.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: DOI:10.1186/s13052-023-01562-0
    reference_title: "Prevalence of depression and anxiety in patients with Tourette syndrome; 1997 to 2022: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the total estimate of the prevalence of depression and anxiety in patients with TS was 36.4%"
    explanation: >-
      Meta-analysis supports anxiety as a common TS comorbidity.
- name: Depression
  category: Behavioral
  description: >-
    Depression is a common psychiatric comorbidity in TS. A high prevalence of
    depression has been reported.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: DOI:10.1186/s13052-023-01562-0
    reference_title: "Prevalence of depression and anxiety in patients with Tourette syndrome; 1997 to 2022: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results of the present study showed that the prevalence of depression
      and anxiety was high in patients with TS.
    explanation: >-
      Meta-analysis supports depression as a frequent comorbidity in TS.
  - reference: PMID:22411257
    reference_title: Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      a high prevalence of
      depression and personality disorders has been reported.
    explanation: >-
      Review confirms high prevalence of depression in TS.
- name: Obsessive-Compulsive Behavior
  category: Behavioral
  description: >-
    Obsessive-compulsive symptoms are an important TS comorbidity.
    OCD is common in TS, and the clinical distinction between compulsions
    and complex tics may be difficult in some cases.
  phenotype_term:
    preferred_term: Obsessive-compulsive behavior
    term:
      id: HP:0000722
      label: Compulsive behaviors
  evidence:
  - reference: PMID:24295616
    reference_title: An introduction to the clinical phenomenology of Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Obsessive-compulsive symptoms and related disorder (OCD) are common in
      TS, and the clinical distinction between compulsions and complex tics may be
      difficult in some cases.
    explanation: >-
      Comprehensive phenomenology review supports OCD as common TS comorbidity.
  - reference: PMID:8708658
    reference_title: A Brazilian cohort of patients with Tourette's syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "compulsive behaviour in 44% of patients"
    explanation: >-
      Brazilian cohort quantifies OCD prevalence at 44% of TS patients.
- name: Sleep Disturbance
  category: Neurologic
  description: >-
    Sleep disorders are very common in patients with Tourette syndrome,
    including insomnia, excessive daytime sleepiness, disorders of arousal,
    persistence of tics during sleep, and periodic limb movements during sleep.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:32554211
    reference_title: Sleep disorders in tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sleep disorders are very common in patients diagnosed with Tourette syndrome"
    explanation: >-
      Systematic review confirms high prevalence of sleep disorders in TS.
  - reference: PMID:32554211
    reference_title: Sleep disorders in tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Insomnia, excessive daytime sleepiness,
      disorders of arousal (sleepwalking, sleeptalking, sleep terrors, and enuresis),
      the persistence of tics during sleep, and presence of periodic limb movements
      during sleep (PLMS) were very frequent in patients with TS.
    explanation: >-
      Specifies the types of sleep disturbances common in TS.
- name: Premonitory Sensory Urges
  category: Neurologic
  description: >-
    Premonitory urges are uncomfortable sensory phenomena that precede tic
    execution and are increasingly recognized as a crucial symptom of TS.
    They consist of premonitory urges and somatic hypersensitivity.
  phenotype_term:
    preferred_term: Premonitory sensory urges
  evidence:
  - reference: PMID:24295616
    reference_title: An introduction to the clinical phenomenology of Tourette syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      The sensory phenomena of TS are increasingly recognized as
      another crucial symptom of TS and consist of premonitory urges and somatic
      hypersensitivity.
    explanation: >-
      Comprehensive phenomenology review identifies sensory phenomena as a
      crucial TS symptom domain.
genetic:
- name: HDC
  gene_term:
    preferred_term: HDC
    term:
      id: hgnc:4855
      label: HDC
  association: Rare pathogenic variant in familial Tourette syndrome
  relationship_type: CAUSATIVE
  notes: >-
    HDC is represented as a rare familial pathogenic gene rather than a common
    explanation for Tourette syndrome overall.
  evidence:
  - reference: PMID:24411733
    reference_title: "Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "has been implicated as a rare genetic cause."
    explanation: >-
      Familial genetics review identifies HDC as one of the two currently
      recognized rare pathogenic single-variant genes for GTS.
- name: SLITRK1
  gene_term:
    preferred_term: SLITRK1
    term:
      id: hgnc:20297
      label: SLITRK1
  association: Rare pathogenic variant in familial Tourette syndrome
  relationship_type: CAUSATIVE
  notes: >-
    SLITRK1 is represented as a rare familial pathogenic gene rather than a
    common explanation for Tourette syndrome overall.
  evidence:
  - reference: PMID:16224024
    reference_title: "Sequence variants in SLITRK1 are associated with Tourette's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "these findings support the association of rare SLITRK1 sequence variants with"
    explanation: >-
      Familial genetics review identifies SLITRK1 as one of the two currently
      recognized rare pathogenic single-variant genes for GTS.
- name: Polygenic genetic liability
  association: Complex multifactorial and polygenic susceptibility
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Most Tourette syndrome cases are modeled as genetically complex, with
    familial clustering and contributions from common, rare, and structural
    variants rather than a single-gene etiology.
  evidence:
  - reference: DOI:10.3390/brainsci15050426
    reference_title: Epidemiology of Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tourette syndrome (TS) is a neurodevelopmental disorder, manifested by
      tics and a variety of behavioral comorbidities that cluster strongly
      within families, suggesting a combination of genetic and environmental
      risk factors.
    explanation: >-
      Epidemiology review supports familial clustering and a combined genetic
      and environmental liability model.
  - reference: DOI:10.3390/ijms25115758
    reference_title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complex and elusive etiology with a significant role of genetic factors"
    explanation: >-
      Structural-variant review supports the interpretation that most GTS is
      genetically heterogeneous rather than explained by a single gene.
diagnosis:
- name: Clinical tic-disorder assessment
  presence: >-
    Diagnosis is clinical and based on tic phenomenology, age at onset,
    duration, impairment, and exclusion of substance- or condition-induced tic
    symptoms.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  evidence:
  - reference: DOI:10.1007/s00787-021-01842-2
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Diagnostic changes between DSM-IV and DSM-5 classifications were taken
      into account and new information has been added regarding differential
      diagnoses, with an emphasis on functional movement disorders in both
      children and adults.
    explanation: >-
      ESSTS assessment guideline supports diagnosis through clinical criteria
      and differential assessment.
- name: Yale Global Tic Severity Scale
  presence: >-
    YGTSS is used to assess tic severity in routine care and clinical research.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  evidence:
  - reference: DOI:10.1007/s00787-021-01842-2
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      We acknowledge that the Yale Global Tic Severity Scale (YGTSS) is still
      the gold standard for assessing tics.
    explanation: >-
      The guideline explicitly identifies YGTSS as the gold-standard tic
      assessment scale.
- name: Biomarkers are investigational
  presence: >-
    Peripheral biomarkers may differentiate groups in research settings but are
    not yet precise or standardized enough for stand-alone clinical diagnosis.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  evidence:
  - reference: DOI:10.3389/fneur.2024.1262057
    reference_title: "Biomarkers and Tourette syndrome: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Larger and more standardized studies are necessary to replicate the
      observed results, elucidate the specificity of the biomarkers for TS, and
      evaluate their precision for use in clinical settings.
    explanation: >-
      Biomarker meta-analysis supports diagnostic caution and further
      validation needs.
differential_diagnoses:
- name: Functional tic-like movement disorder
  description: >-
    Functional tic-like movements can resemble primary tics but often have
    atypical onset, suppressibility, and treatment-response patterns.
  disease_term:
    preferred_term: functional tic-like movement disorder
  evidence:
  - reference: DOI:10.1007/s00787-021-01842-2
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      new information has been added regarding differential diagnoses, with an
      emphasis on functional movement disorders in both children and adults.
    explanation: >-
      ESSTS guideline highlights functional movement disorders in tic-disorder
      differential diagnosis.
- name: Stereotypic movement disorder
  description: >-
    Stereotypies can be mistaken for tics and require distinction by
    phenomenology, age at onset, rhythm, and suppressibility.
  disease_term:
    preferred_term: stereotypic movement disorder
    term:
      id: MONDO:0002265
      label: stereotypic movement disorder
  evidence:
  - reference: DOI:10.1007/s00787-021-01842-2
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      assessments supporting the differential diagnosis process are given as
      well as tests to analyse cognitive abilities, emotional functions and
      motor skills.
    explanation: >-
      The abstract supports motor-skill and differential-diagnosis assessment,
      though it does not name stereotypic movement disorder.
- name: Tic disorder
  description: >-
    Other tic disorders can share motor or vocal tics but do not necessarily
    meet full Tourette syndrome duration and motor-plus-vocal criteria.
  disease_term:
    preferred_term: tic disorder
    term:
      id: MONDO:0002420
      label: tic disorder
  evidence:
  - reference: DOI:10.1007/s00787-021-01842-2
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Now, we present an updated version 2.0 of these European clinical
      guidelines for Tourette syndrome and other tic disorders, part I:
      assessment.
    explanation: >-
      The guideline scope supports distinguishing Tourette syndrome from other
      tic disorders.
- name: Obsessive-compulsive disorder
  description: >-
    OCD frequently co-occurs with TS and can dominate impairment, but
    compulsions are distinguished from tics by phenomenology and intent.
  disease_term:
    preferred_term: obsessive-compulsive disorder
    term:
      id: MONDO:0008114
      label: obsessive-compulsive disorder
  evidence:
  - reference: DOI:10.1007/s00787-021-01842-2
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      Recommendations are provided for scales for the assessment of tics and
      psychiatric comorbidities in patients with TS not only in routine clinical
      practice, but also in the context of clinical research.
    explanation: >-
      The guideline supports psychiatric comorbidity assessment; OCD-specific
      distinction is inferred from TS clinical practice and HPO phenotype
      mapping.
treatments:
- name: Behavioral therapy for tics
  description: >-
    Psychoeducation and behavioral approaches, including CBIT, habit-reversal
    training, and exposure-response prevention, are preferred first-line
    nonpharmacologic treatments when available and feasible.
  treatment_term:
    preferred_term: cognitive behavior therapy
    term:
      id: MAXO:0000883
      label: cognitive behavior therapy
  target_phenotypes:
  - preferred_term: Tics
    term:
      id: HP:0100033
      label: Tics
  evidence:
  - reference: DOI:10.1007/s00787-021-01899-z
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The first preference should be given to psychoeducation and to behavioral
      approaches, as it strengthens the patients’ self-regulatory control and
      thus his/her autonomy.
    explanation: >-
      ESSTS guideline abstract supports psychoeducation and behavioral
      approaches as preferred first-line management for TS.
- name: Dopamine-blocking pharmacotherapy
  description: >-
    Dopamine-blocking pharmacotherapy, preferably aripiprazole, is used when
    behavioral approaches are ineffective, unavailable, or infeasible.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: aripiprazole
      term:
        id: CHEBI:31236
        label: aripiprazole
  target_phenotypes:
  - preferred_term: Tics
    term:
      id: HP:0100033
      label: Tics
  target_mechanisms:
  - target: Dopamine-Modulated Tic Circuit Output
    treatment_effect: MODULATES
    description: >-
      Dopamine-blocking agents are modeled as modulating dopamine-sensitive tic
      circuit output.
  evidence:
  - reference: DOI:10.1007/s00787-021-01899-z
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The largest amount of evidence supports the use of dopamine blocking
      agents, preferably aripiprazole because of a more favorable profile of
      adverse events than first- and second-generation antipsychotics.
    explanation: >-
      Guideline evidence supports dopamine-blocking agents, with aripiprazole
      preferred because of adverse-event profile.
- name: Alpha-2 agonist pharmacotherapy for ADHD comorbidity
  description: >-
    Clonidine and guanfacine can be considered when Tourette syndrome coexists
    with attention deficit hyperactivity disorder.
  context: Co-existing ADHD
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: clonidine
      term:
        id: CHEBI:46631
        label: clonidine
    - preferred_term: guanfacine
      term:
        id: CHEBI:5558
        label: guanfacine
  target_phenotypes:
  - preferred_term: Tics
    term:
      id: HP:0100033
      label: Tics
  evidence:
  - reference: DOI:10.1007/s00787-021-01899-z
    reference_title: "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Other agents that can be considered include tiapride, risperidone, and
      especially in case of co-existing attention deficit hyperactivity
      disorder (ADHD), clonidine and guanfacine.
    explanation: >-
      Guideline evidence supports clonidine and guanfacine consideration in
      TS with co-existing ADHD.
clinical_trials:
- name: NCT04007991
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase 2b randomized placebo-controlled study of ecopipam tablets in
    children and adolescents with Tourette syndrome.
  target_phenotypes:
  - preferred_term: Tics
    term:
      id: HP:0100033
      label: Tics
  evidence:
  - reference: clinicaltrials:NCT04007991
    reference_title: "Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam in Children and Adolescents With Tourette's Syndrome"
    supports: SUPPORT
    snippet: >-
      This study evaluates the effect of ecopipam tablets in children and
      adolescents in the treatment of Tourette's Syndrome (TS).
    explanation: >-
      ClinicalTrials.gov record documents a pediatric ecopipam trial targeting
      TS.
- name: NCT05615220
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Phase 3 multicenter randomized-withdrawal study evaluating maintenance of
    ecopipam efficacy, safety, and tolerability in Tourette disorder.
  target_phenotypes:
  - preferred_term: Tics
    term:
      id: HP:0100033
      label: Tics
  evidence:
  - reference: clinicaltrials:NCT05615220
    reference_title: "A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults With Tourette's Disorder"
    supports: SUPPORT
    snippet: >-
      This Phase 3 multicenter study evaluates the maintenance of efficacy,
      safety and tolerability of ecopipam tablets in children, adolescents and
      adults in the treatment of Tourette's Disorder (TD).
    explanation: >-
      ClinicalTrials.gov record documents a late-stage ecopipam trial in TD.
- name: NCT02674321
  phase: PHASE_I
  status: COMPLETED
  description: >-
    Pilot study of SD-809/deutetrabenazine for moderate to severe Tourette
    syndrome.
  target_phenotypes:
  - preferred_term: Tics
    term:
      id: HP:0100033
      label: Tics
  evidence:
  - reference: clinicaltrials:NCT02674321
    reference_title: A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome
    supports: SUPPORT
    snippet: >-
      The purpose of this study is to evaluate safety, tolerability and
      preliminary efficacy of SD-809 in the treatment of motor and phonic tics
      of Tourette Syndrome and to evaluate the pharmacokinetic of SD-809 and
      its metabolites.
    explanation: >-
      ClinicalTrials.gov record documents deutetrabenazine testing for motor
      and phonic tics.
datasets:
- accession: DOI:10.3390/ijms25115758
  title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
  description: >-
    Familial whole-genome sequencing dataset of 17 multiplex families with 80
    TS patients, used to identify structural variants and enriched biological
    processes.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 80
  conditions:
  - familial Tourette syndrome
  - structural variants
  publication: DOI:10.3390/ijms25115758
  evidence:
  - reference: DOI:10.3390/ijms25115758
    reference_title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The study group comprised 17 multiplex families with 80 patients.
    explanation: >-
      The abstract describes the human familial WGS cohort.
  findings:
  - statement: Familial TS structural variants were enriched for synaptic vesicle endocytosis and neurite outgrowth signaling.
    evidence:
    - reference: DOI:10.3390/ijms25115758
      reference_title: Structural Variants and Implicated Processes Associated with Familial Tourette Syndrome
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Enrichment analysis showed that identified structural variants affected
        synaptic vesicle endocytosis, cell leading-edge organization, and
        signaling for neurite outgrowth.
      explanation: >-
        Captures the principal pathway-enrichment finding from the dataset.
- accession: DOI:10.3389/fneur.2024.1262057
  title: "Biomarkers and Tourette syndrome: a systematic review and meta-analysis"
  description: >-
    Systematic-review and meta-analysis dataset of peripheral biomarkers in TS
    case-control studies.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  conditions:
  - Tourette syndrome
  - control
  publication: DOI:10.3389/fneur.2024.1262057
  evidence:
  - reference: DOI:10.3389/fneur.2024.1262057
    reference_title: "Biomarkers and Tourette syndrome: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 81 studies were identified, out of which 60 met the
      eligibility criteria for inclusion in the meta-analysis.
    explanation: >-
      The abstract describes the evidence base for the biomarker meta-analysis.
  findings:
  - statement: Multiple immune, amino-acid, mineral, and neurotrophic markers differed between TS and controls.
    evidence:
    - reference: DOI:10.3389/fneur.2024.1262057
      reference_title: "Biomarkers and Tourette syndrome: a systematic review and meta-analysis"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        13 comparisons were statistically significant [CD3+ T cell, CD4+ T
        cell, CD4+ T cell to CD8+ T cell ratio, NK-cell, anti-streptolysin O
        antibodies, anti-DNase antibodies, glutamic acid (Glu), aspartic acid
        (Asp), ferritin (Fe), zinc (Zn), lead (Pb), vitamin D, and brain-derived
        neurotrophic factor (BDNF)].
      explanation: >-
        Captures the meta-analysis finding of statistically significant
        biomarker differences.
notes: >-
  Pathophysiology entries are separated into genetic, synaptic,
  neurodevelopmental, circuit, neurotransmission, and peripheral-biomarker nodes
  so causal relationships can be represented with downstream edges.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 56 citations 2026-04-24T17:16:47.024834

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Tourette Syndrome
MONDO ID: (if available)
Category: Psychiatric

Research Objectives

Please provide a comprehensive research report on Tourette Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Tourette Syndrome (TS) — Disease Characteristics Research Report

0. Executive summary

Tourette syndrome (TS; also “Gilles de la Tourette syndrome”) is a childhood-onset neurodevelopmental disorder defined by multiple motor tics plus at least one vocal/phonic tic, persisting for >1 year, with onset before age 18 and not attributable to substances or another medical condition. (abbasi2023prevalenceofdepression pages 1-2, jiang2024biomarkersandtourette pages 1-2)

In recent U.S. nationally representative survey data (NSCH 2016–2022), parent/guardian-reported clinician-diagnosed TS prevalence in ages 0–17 was 0.23% overall (0.35% in boys vs 0.11% in girls), with no significant prevalence change from 2016 to 2022. (xiong2024prevalenceoftourette pages 1-2)

1. Disease information

1.1 Disease overview (current understanding)

Core definition (DSM-5 framing, as summarized in recent peer-reviewed literature): multiple motor tics and one or more vocal tics, with onset before 18 years, tics persisting for >1 year, and symptoms not explained by substances or another neurological condition. (abbasi2023prevalenceofdepression pages 1-2)

Key concept—tic: tics are described in guidelines and systematic reviews as “sudden, rapid, recurrent, non-rhythmic motor movements or vocalisations/vocalizations.” (szejko2022europeanclinicalguidelines pages 1-2, amico2024efficacyofnonpharmacological pages 1-2)

Evidence source type: these definitions and broad disease characterizations are drawn from aggregated disease-level resources (clinical guidelines and systematic reviews/meta-analyses), not individual EHRs. (szejko2022europeanclinicalguidelines pages 6-8, abbasi2023prevalenceofdepression pages 1-2)

1.2 Synonyms / alternative names

Tourette syndrome (TS) (xiong2024prevalenceoftourette pages 1-2)
Gilles de la Tourette syndrome (GTS) (fichna2024structuralvariantsand pages 1-2)

1.3 Key identifiers (ontology / coding)

The retrieved evidence corpus explicitly notes alignment with DSM-5 and ICD-11 criteria in the European Society for the Study of Tourette Syndrome (ESSTS) guidelines update, but does not include the exact ICD-10/ICD-11 codes, MeSH ID, OMIM ID(s), Orphanet ID, or MONDO ID in the accessible text snippets. (mullervahl2022europeanclinicalguidelines pages 3-4)

Actionable note for knowledge-base curation: obtain these identifiers from authoritative terminologies (ICD-10/11 browser, MeSH, MONDO, OMIM, Orphanet). The ESSTS summary confirms DSM-5/ICD-11 harmonization but does not provide code strings in the retrieved passages. (mullervahl2022europeanclinicalguidelines pages 3-4)

2. Etiology

2.1 Causal factors (genetic, environmental, mechanistic)

TS is strongly familial and genetically influenced, but exhibits complex architecture spanning polygenic common-variant effects and rare/structural variants. (yilmaz2025epidemiologyoftourette pages 1-4, fichna2024structuralvariantsand pages 1-2)

Heritability: an epidemiology review reports genome-wide study heritability estimates of 0.77–0.92 and monozygotic twin concordance of 64.3%. (yilmaz2025epidemiologyoftourette pages 1-4)
Polygenic architecture: a large GWAS meta-analysis summarized in the evidence indicates SNP heritability ~13.8% and gene-level associations including BCL11B, NDFIP2, RBM26. (strom2025geneticriskof pages 73-75)
Rare/structural variants: a 2024 familial whole-genome sequencing study found 70 putative pathogenic structural variants (SVs), including exonic deletions in LDLRAD4, B2M, USH2A, ZNF765 and recurrent insertions in GOLM1 and DISC1 that co-segregated in multiple families. (fichna2024structuralvariantsand pages 1-2)

Direct abstract-quote support: the 2024 familial SV study states: “Seventy putative pathogenic variants… were identified,” and highlights “uncommon insertions in GOLM1 and DISC1” and enriched processes including synaptic vesicle endocytosis and neurite outgrowth signaling. (fichna2024structuralvariantsand pages 1-2)

2.2 Risk factors

Genetic risk factors

Family clustering / heritability: high heritability supports genetic susceptibility as a major risk factor. (yilmaz2025epidemiologyoftourette pages 1-4)
SV/CNV gene candidates and pathways: SVs affecting genes such as NRXN3, DISC1, CACNA2D3, USH2A and immune-related B2M are implicated in familial TS, with enrichment in synaptic and neurite-related processes. (fichna2024structuralvariantsand pages 4-5)

Environmental / psychosocial risk factors

The ESSTS assessment guideline emphasizes differential diagnosis and clinical context but does not provide a quantitative catalog of environmental exposures causing TS. However, it highlights that functional tic-like movements may be associated with traumatic events and show poor response to anti-tic medication—important for diagnostic risk stratification and avoiding misattribution. (szejko2022europeanclinicalguidelines pages 6-8)

2.3 Protective factors

No specific genetic or environmental protective factors were identifiable in the retrieved evidence snippets.

2.4 Gene–environment interaction

A monozygotic twin design study (tic spectrum disorder, encompassing TS and chronic tic disorder) was explicitly motivated by “key uncertainties concerning the role of environmental influences,” and identified environmentally influenced transcriptional signals (e.g., RNY1 associated with tic severity), though with limited sample size and no multiple-testing significant methylation probes. (dalsberg2026transcriptomeandepigenomewide pages 1-2)

3. Phenotypes

3.1 Core phenotypes and HPO mapping (suggested)

Core tic phenotypes (symptoms/signs): - Motor tics (HPO suggestion: Motor tic; commonly HP:0002459) (supported conceptually by TS definition) (abbasi2023prevalenceofdepression pages 1-2) - Vocal/phonic tics (HPO suggestion: Vocal tic; commonly HP:0030220) (abbasi2023prevalenceofdepression pages 1-2) - Premonitory urges (HPO suggestion: Premonitory urge; no specific HPO term confirmed in evidence; clinically captured by PUTS) (szejko2022europeanclinicalguidelines pages 11-12)

Common neuropsychiatric comorbidities (behavioral/psychiatric phenotypes): - ADHD (HPO suggestion: Attention deficit hyperactivity disorder) (yilmaz2025epidemiologyoftourette pages 9-11) - OCD/obsessive–compulsive symptoms (HPO suggestion: Obsessive-compulsive behavior) (yilmaz2025epidemiologyoftourette pages 9-11) - Anxiety (HPO suggestion: Anxiety) (abbasi2023prevalenceofdepression pages 1-2) - Depression (HPO suggestion: Depressive episode) (abbasi2023prevalenceofdepression pages 1-2)

3.2 Phenotype characteristics (onset, severity, course, frequency)

Typical onset: tics usually begin around ages 4–6 (or ~5–6 in ESSTS assessment). (yilmaz2025epidemiologyoftourette pages 8-9, szejko2022europeanclinicalguidelines pages 1-2)
Peak severity: typically around 8–12 years (often 10–12). (yilmaz2025epidemiologyoftourette pages 8-9, yilmaz2025epidemiologyoftourette pages 1-4)
Course: waxing/waning; many improve in adolescence/young adulthood; ~one-third may be tic-free by adulthood, while 50–80% may have at least mild tics after age 16. (yilmaz2025epidemiologyoftourette pages 8-9)

3.3 Quality-of-life impact

A U.S. population study notes TS is associated with functional impairments “across physical, psychological, academic, family, and social domains” and increased bullying involvement. (xiong2024prevalenceoftourette pages 1-2)

3.4 Psychiatric comorbidity burden (statistics)

An epidemiology review reports ~85% with ≥1 psychiatric comorbidity and 57% with ≥2. (yilmaz2025epidemiologyoftourette pages 8-9)

A 2023 systematic review/meta-analysis estimated pooled prevalence of depression 36.4% and anxiety 53.5% in TS, increasing with mean age. (abbasi2023prevalenceofdepression pages 1-2)

4. Genetic / molecular information

4.1 Causal genes and pathogenic variants

TS is typically not monogenic. The familial SV study notes that “only single variants in HDC and SLITRK1 are currently classified as pathogenic by HPO,” emphasizing heterogeneity. (fichna2024structuralvariantsand pages 1-2)

4.2 Structural variants and implicated genes (2024 study)

In 17 multiplex families (80 patients), WGS-based SV analysis identified: - Exonic deletions in LDLRAD4, B2M, USH2A, ZNF765 (fichna2024structuralvariantsand pages 1-2) - Recurrent insertions co-segregating in GOLM1 and DISC1 (fichna2024structuralvariantsand pages 1-2) - Additional SV/SNV overlap genes highlighted include NRXN3, CACNA2D3, PSD3, ZNF407, EYS (fichna2024structuralvariantsand pages 4-5)

4.3 Polygenic risk and implicated loci (recent large-scale genetics)

A GWAS meta-analysis summary reports: - SNP heritability ~13.8% - Gene-level significant signals: BCL11B, NDFIP2, RBM26 - Enrichment in cortico-striato-thalamo-cortical (CSTC) circuit regions and neuronal cell types including medium spiny neurons. (strom2025geneticriskof pages 73-75)

4.4 Pathway/process annotations (GO/Reactome/KEGG suggestions)

Based on SV enrichment and GWAS enrichment summaries: - GO biological process suggestions: synaptic vesicle endocytosis, neurite outgrowth, neuronal migration, regulation of neurotransmission, dendritic spine organization (fichna2024structuralvariantsand pages 4-5, fichna2024structuralvariantsand pages 1-2) - KEGG/pathway suggestions: CSTC circuit functional modules (not a single KEGG pathway), and (from twin study enrichment) ribosome, nucleocytoplasmic transport, nicotine addiction (as an enriched KEGG set in peripheral blood transcriptome) (dalsberg2026transcriptomeandepigenomewide pages 1-2)

5. Environmental information

The retrieved sources did not provide a definitive exposure-based environmental etiology for primary TS. The ESSTS assessment guideline provides practical clinical differentiation from functional tic-like disorders (which may be triggered by psychosocial stressors/trauma and show atypical features), which is relevant to avoiding misclassification. (szejko2022europeanclinicalguidelines pages 6-8)

6. Mechanism / pathophysiology

6.1 Circuit-level mechanisms (current consensus)

Recent epidemiology and treatment sources converge on CSTC circuit dysfunction and dopaminergic involvement: - A systematic review/meta-analysis on cannabis-based medicine states TS “is associated with structural and functional alterations in corticostriatal circuits and neurochemical imbalances.” (serag2024efficacyofcannabisbased pages 4-5) - A behavioral-treatment systematic review likewise notes dysfunction of the “cortico–striatal–thalamus–cortical circuit” and dopaminergic/serotonergic dysregulation. (amico2024efficacyofnonpharmacological pages 1-2)

6.2 Neuroimmune and peripheral biomarker findings (2024)

A 2024 biomarker meta-analysis identified significant differences in several peripheral markers between TS and controls (e.g., T cell subsets, anti-streptolysin O antibodies, amino acids, ferritin/iron, zinc, lead, vitamin D, BDNF), while noting there is currently no biological gold-standard test for TS. (jiang2024biomarkersandtourette pages 1-2)

6.3 Proposed causal chain (integrated, evidence-aligned)

1) Genetic susceptibility (polygenic and rare/SV) impacts synaptic/neurodevelopmental processes and CSTC circuit development and function. (strom2025geneticriskof pages 73-75, fichna2024structuralvariantsand pages 4-5) 2) Circuit-level dysregulation (particularly dopaminergic modulation in CSTC pathways) alters motor control gating and tic suppression mechanisms. (amico2024efficacyofnonpharmacological pages 1-2, serag2024efficacyofcannabisbased pages 4-5) 3) Clinical manifestation: childhood-onset motor and vocal tics with waxing/waning course, commonly accompanied by ADHD/OCD/anxiety/depression that amplifies impairment and QoL impact. (yilmaz2025epidemiologyoftourette pages 8-9, abbasi2023prevalenceofdepression pages 1-2)

6.4 Cell types and CL term suggestions

Medium spiny neurons (striatum) (CL suggestion: striatal medium spiny neuron) (strom2025geneticriskof pages 73-75)
Cortical excitatory neurons / inhibitory interneurons (CL suggestions: glutamatergic neuron, GABAergic interneuron) (strom2025geneticriskof pages 73-75)

7. Anatomical structures affected

Primary involvement is within the central nervous system, particularly CSTC circuit nodes: - Striatum (caudate, putamen, nucleus accumbens) and frontal cortical regions are implicated by post-GWAS enrichment. (strom2025geneticriskof pages 73-75)

UBERON suggestions: - Striatum (UBERON:0002435), caudate nucleus (UBERON:0001876), putamen (UBERON:0001875), nucleus accumbens (UBERON:0001882), prefrontal cortex (UBERON:0001873) — suggested for annotation; exact IDs should be verified in Uberon.

8. Temporal development

Onset: typically early childhood (~4–6 years). (yilmaz2025epidemiologyoftourette pages 8-9)
Peak: late childhood/pre-adolescence (~8–12 years). (yilmaz2025epidemiologyoftourette pages 8-9)
Progression: waxing/waning; many improve in late adolescence/early adulthood; persistence is common but often milder. (yilmaz2025epidemiologyoftourette pages 8-9)

9. Inheritance and population

9.1 Epidemiology (recent and quantitative)

Domain	Metric	Quantitative finding	Population / notes	Evidence (citation id)	Source URL + year
Epidemiology	US diagnosed prevalence, ages 0–17	0.23% overall	National Survey of Children’s Health (NSCH), parent/guardian-reported clinician diagnosis, United States, 2016–2022	(xiong2024prevalenceoftourette pages 1-2)	https://doi.org/10.1186/s12889-024-20216-2 (2024)
Epidemiology	US prevalence by age	<0.01% (0–2 y); 0.05% (3–5 y); 0.28% (6–11 y); 0.38% (12–17 y)	Weighted prevalence in NSCH 2016–2022	(xiong2024prevalenceoftourette pages 1-2)	https://doi.org/10.1186/s12889-024-20216-2 (2024)
Epidemiology	US prevalence by sex	0.35% boys vs 0.11% girls	NSCH 2016–2022	(xiong2024prevalenceoftourette pages 1-2)	https://doi.org/10.1186/s12889-024-20216-2 (2024)
Epidemiology	US trend over time	No significant change from 2016 to 2022	NSCH trend analysis	(xiong2024prevalenceoftourette pages 1-2)	https://doi.org/10.1186/s12889-024-20216-2 (2024)
Epidemiology	Global / literature prevalence in children & adolescents	About 0.3–0.77% in meta-analytic estimates; broader study range 0.05%–1.1%	Across population studies; estimates vary by ascertainment and methodology	(yilmaz2025epidemiologyoftourette pages 1-4)	https://doi.org/10.3390/brainsci15050426 (2025)
Epidemiology	Global prevalence in children/adolescents	Approximately 0.7%	Review of biomarker literature cites global prevalence in children/adolescents	(jiang2024biomarkersandtourette pages 1-2)	https://doi.org/10.3389/fneur.2024.1262057 (2024)
Epidemiology	Adult prevalence	About 0.01%–0.011%	Much lower than in childhood/adolescence	(yilmaz2025epidemiologyoftourette pages 1-4)	https://doi.org/10.3390/brainsci15050426 (2025)
Epidemiology	Male:female ratio	About 4:1 overall in childhood; reported study range 1.58:1 to 9.0:1; falls to about 2.33:1 in adulthood	Sex difference is robust but magnitude varies across studies	(yilmaz2025epidemiologyoftourette pages 8-9, yilmaz2025epidemiologyoftourette pages 1-4)	https://doi.org/10.3390/brainsci15050426 (2025)
Comorbidity	Any psychiatric comorbidity	About 85% have ≥1 psychiatric comorbidity; 57% have ≥2	Family/clinical cohorts summarized in epidemiology review	(yilmaz2025epidemiologyoftourette pages 8-9)	https://doi.org/10.3390/brainsci15050426 (2025)
Comorbidity	ADHD	About 50%	Commonest neurodevelopmental comorbidity in TS	(yilmaz2025epidemiologyoftourette pages 9-11)	https://doi.org/10.3390/brainsci15050426 (2025)
Comorbidity	OCD	Reported prevalence 7%–50%	Frequent and often disabling; about 10% have both ADHD and OCD	(yilmaz2025epidemiologyoftourette pages 9-11)	https://doi.org/10.3390/brainsci15050426 (2025)
Comorbidity	Anxiety	Pooled prevalence 53.5% (95% CI 39.9–66.6%)	Systematic review/meta-analysis, 12 studies, n=3812	(abbasi2023prevalenceofdepression pages 1-2)	https://doi.org/10.1186/s13052-023-01562-0 (2023)
Comorbidity	Depression	Pooled prevalence 36.4% (95% CI 21.1–54.9%)	Systematic review/meta-analysis, 12 studies, n=3812	(abbasi2023prevalenceofdepression pages 1-2)	https://doi.org/10.1186/s13052-023-01562-0 (2023)
Natural history	Typical age at onset	Usually 4–6 years; assessment guideline notes around 5–6 years	Childhood-onset disorder	(yilmaz2025epidemiologyoftourette pages 8-9, szejko2022europeanclinicalguidelines pages 1-2)	https://doi.org/10.3390/brainsci15050426 (2025); https://doi.org/10.1007/s00787-021-01842-2 (2022)
Natural history	Age of peak severity	Around 8–12 years; commonly 10–12 years or “just before puberty”	Tic severity generally worsens into late childhood/pre-adolescence	(yilmaz2025epidemiologyoftourette pages 8-9, yilmaz2025epidemiologyoftourette pages 1-4)	https://doi.org/10.3390/brainsci15050426 (2025)
Natural history	Improvement by adulthood	About three-quarters improve in older teens/young adulthood	Many continue to have residual symptoms despite improvement	(xiong2024prevalenceoftourette pages 1-2, yilmaz2025epidemiologyoftourette pages 8-9)	https://doi.org/10.1186/s12889-024-20216-2 (2024); https://doi.org/10.3390/brainsci15050426 (2025)
Natural history	Tic-free by adulthood	Roughly one-third may be tic-free by adulthood	Review-based estimate	(yilmaz2025epidemiologyoftourette pages 8-9)	https://doi.org/10.3390/brainsci15050426 (2025)
Natural history	Persistent symptoms into adulthood	About 50–80% of those >16 years have at least mild tics; another source notes roughly three-quarters still have tic symptoms into early adulthood	Persistence is common even when severity declines	(yilmaz2025epidemiologyoftourette pages 8-9, xiong2024prevalenceoftourette pages 1-2)	https://doi.org/10.3390/brainsci15050426 (2025); https://doi.org/10.1186/s12889-024-20216-2 (2024)
Natural history	Course pattern	Waxing and waning / fluctuating	Typical course rather than steadily progressive disease	(abbasi2023prevalenceofdepression pages 1-2, szejko2022europeanclinicalguidelines pages 1-2)	https://doi.org/10.1186/s13052-023-01562-0 (2023); https://doi.org/10.1007/s00787-021-01842-2 (2022)

Table: This table condenses recent quantitative data on Tourette syndrome prevalence, sex differences, psychiatric comorbidity burden, and typical clinical course. It is useful as a quick reference for population-level characteristics and disease trajectory when building a disease knowledge base entry.

Key recent statistic (U.S.): prevalence 0.23% in ages 0–17 from 2016–2022 NSCH; stable over time; higher in boys than girls. (xiong2024prevalenceoftourette pages 1-2)

9.2 Sex ratio

Literature syntheses report a male:female ratio around ~4:1 in childhood, decreasing into adulthood. (yilmaz2025epidemiologyoftourette pages 8-9, yilmaz2025epidemiologyoftourette pages 1-4)

10. Diagnostics

10.1 Clinical criteria and assessment approach

Diagnosis is clinical, supported by careful phenomenology and comorbidity assessment. ESSTS assessment guidance states that routine neuroimaging/EEG “do not add value in establishing the diagnosis of a tic disorder” and should be performed only if clinically indicated. (szejko2022europeanclinicalguidelines pages 6-8)

10.2 Rating scales (ESSTS 2022)

Recommended tools include: - Yale Global Tic Severity Scale (YGTSS) (gold standard; recommended) (szejko2022europeanclinicalguidelines pages 11-12) - Premonitory Urge for Tics Scale (PUTS) (recommended) (szejko2022europeanclinicalguidelines pages 11-12) - QoL measures: GTS-QOL and C&A-GTS-QOL (recommended) (szejko2022europeanclinicalguidelines pages 11-12) - OCD severity: Y-BOCS / CY-BOCS / CY-BOCS-II (recommended) (szejko2022europeanclinicalguidelines pages 11-12) - ADHD scales used by experts: SNAP, CAARS, CBRS, WURS (szejko2022europeanclinicalguidelines pages 11-12)

10.3 Differential diagnosis (including functional tic-like behaviors)

ESSTS guidance distinguishes primary tics from: - Stereotypies: earlier onset (0–3 years), quasi-rhythmic, not typically associated with premonitory urge. (szejko2022europeanclinicalguidelines pages 6-8) - Functional tic-like movements/vocalizations: atypical features include absent premonitory urges, inability to suppress, adult onset, female preponderance, and poor response to anti-tic medication; functional vocalisations may include speech blocking and association with traumatic events. (szejko2022europeanclinicalguidelines pages 6-8)

11. Outcome / prognosis

Most individuals improve in adolescence/young adulthood, but persistence of at least mild symptoms is common. (yilmaz2025epidemiologyoftourette pages 8-9)

Comorbid psychiatric disorders are common and materially influence disability and quality of life (e.g., pooled anxiety ~53.5% and depression ~36.4% in a 2023 meta-analysis). (abbasi2023prevalenceofdepression pages 1-2)

12. Treatment

12.1 Guideline-based treatment algorithm (ESSTS)

The ESSTS v2.0 summary provides an updated decision-tree algorithm for shared decision-making in TS treatment. (mullervahl2022europeanclinicalguidelines media b45307e9)

12.2 Evidence-based interventions and real-world implementation

Intervention	Mechanism / class	Typical use-case / indication	Key efficacy statistics	Key safety / monitoring issues	Best supporting citation + URL/year
CBIT / HRT / ERP (behavior therapy)	Behavioral therapy; HRT/CBIT strengthen tic awareness and competing responses; ERP targets suppression while tolerating premonitory urges	First-line when psychoeducation alone is insufficient; recommended for children and adults with Tourette syndrome or chronic tic disorder	ESSTS: HRT/CBIT and ERP are recommended first-line psychological interventions; pediatric RCT/systematic-review evidence shows CBIT reduced YGTSS total tic score by 7.6 points vs 3.5 in controls; group CBIT produced 32% motor-tic reduction maintained at 3 months; HRT improved motor tics but less consistent effect on vocal tics (amico2024efficacyofnonpharmacological pages 3-5, amico2024efficacyofnonpharmacological pages 5-6, amico2024efficacyofnonpharmacological pages 6-8, mullervahl2022europeanclinicalguidelines pages 1-3)	Requires trained therapists; access can be limited; dropout can reduce effectiveness in practice; monitor adherence, family support, and comorbid ADHD/OCD/anxiety that may affect engagement (amico2024efficacyofnonpharmacological pages 3-5, amico2024efficacyofnonpharmacological pages 6-8)	ESSTS psychological guideline: https://doi.org/10.1007/s00787-021-01845-z (2022); pediatric review: https://doi.org/10.3390/app14209466 (2024)
Telehealth / internet-delivered ERP or CBIT	Remote therapist-supported behavioral therapy via videoconference or internet platform	Useful when access to trained therapists or travel is a barrier; increasingly implemented in youth	Telehealth CBIT decreased YGTSS by 7.8 points vs 6.5 face-to-face; CBIT-VoIP showed 7.25-point fall vs 1.75 in controls; meta-analysis of therapist-supported remote therapy found pooled YGTSS-TTSS MD -2.22 (95% CI -3.16 to -1.29), and versus online psychoeducation MD -2.37 (95% CI -3.64 to -1.10) with similar efficacy to face-to-face care (amico2024efficacyofnonpharmacological pages 6-8, xu2025efficacyoftherapistsupported pages 5-6)	Improves access and continuity; requires caregiver cooperation, internet/device access, and therapist support; durability appears favorable but long-term follow-up remains important (xu2025efficacyoftherapistsupported pages 5-6, amico2024efficacyofnonpharmacological pages 3-5)	Telehealth meta-analysis: https://doi.org/10.3389/fpsyt.2025.1521947 (2025); pediatric review: https://doi.org/10.3390/app14209466 (2024)
Aripiprazole	Dopamine receptor blocking/modulating antipsychotic (partial D2 agonist)	Preferred first-line medication when behavioral therapy is ineffective, unavailable, or insufficient; commonly used in children and adults	ESSTS 2022: among medications, the largest amount of evidence supports dopamine-blocking agents, preferably aripiprazole because of a more favorable adverse-event profile; average expected tic reduction with medication is about 50% overall, though individual response varies (roessner2022europeanclinicalguidelines pages 1-2, roessner2022europeanclinicalguidelines pages 8-9, mullervahl2022europeanclinicalguidelines pages 3-4)	Start low, go slow; monitor weight/metabolic effects, sedation, extrapyramidal symptoms, prolactin-related effects, cardiovascular/ECG issues; taper gradually to avoid withdrawal dyskinesia (roessner2022europeanclinicalguidelines pages 8-9)	ESSTS pharmacologic guideline: https://doi.org/10.1007/s00787-021-01899-z (2022)
Tiapride	Dopamine receptor antagonist (benzamide antipsychotic)	Medication option with established evidence, often used in Europe for tic reduction	ESSTS identifies tiapride among antipsychotics with best-established evidence/clinical experience; part of the medication group where average tic reduction is approximately 50% (roessner2022europeanclinicalguidelines pages 8-9, roessner2022europeanclinicalguidelines pages 1-2)	Off-label in many settings; monitor EPS, sedation, cardiovascular effects, and general antipsychotic adverse effects; use lower doses than in psychosis and titrate slowly (roessner2022europeanclinicalguidelines pages 8-9)	ESSTS pharmacologic guideline: https://doi.org/10.1007/s00787-021-01899-z (2022)
Risperidone	Second-generation antipsychotic; dopamine/serotonin receptor antagonist	Evidence-based pharmacologic option for tic reduction; also considered when OCD symptoms coexist	ESSTS lists risperidone among recommended antipsychotics with substantial evidence; average medication-related tic reduction is around 50% overall (roessner2022europeanclinicalguidelines pages 8-9, roessner2022europeanclinicalguidelines pages 1-2)	Higher concern for weight gain/metabolic effects, prolactin elevation, sedation, movement disorders, ECG/cardiovascular effects; taper gradually (roessner2022europeanclinicalguidelines pages 8-9)	ESSTS pharmacologic guideline: https://doi.org/10.1007/s00787-021-01899-z (2022)
Clonidine	Alpha-2 adrenergic agonist / noradrenergic agent	Especially useful for mild-to-moderate tics with co-existing ADHD; often favored in pediatric practice	ESSTS/AAN review gives moderate confidence for tic benefit vs placebo; recommended first-line pharmacologic option when ADHD co-occurs rather than for severe tics alone (roessner2022europeanclinicalguidelines pages 1-2, roessner2022europeanclinicalguidelines pages 8-9)	Monitor blood pressure, pulse, sedation, dizziness; taper carefully to avoid rebound hypertension; benefit for tics alone is limited compared with antipsychotics (roessner2022europeanclinicalguidelines pages 8-9)	ESSTS pharmacologic guideline: https://doi.org/10.1007/s00787-021-01899-z (2022)
Guanfacine	Alpha-2 adrenergic agonist	Similar role to clonidine, mainly when ADHD coexists and tics are mild-to-moderate	ESSTS highlights guanfacine for TS with ADHD, but evidence is weaker than for antipsychotics; useful as part of individualized treatment plans (roessner2022europeanclinicalguidelines pages 1-2, roessner2022europeanclinicalguidelines pages 8-9)	Monitor blood pressure, pulse, sedation/fatigue; overall evidence for tic reduction is less robust than for antipsychotics (roessner2022europeanclinicalguidelines pages 1-2, roessner2022europeanclinicalguidelines pages 8-9)	ESSTS pharmacologic guideline: https://doi.org/10.1007/s00787-021-01899-z (2022)
Botulinum toxin injections	Peripheral chemodenervation of overactive muscles / focal anti-tic intervention	Focal, bothersome, treatment-resistant motor or vocal tics	ESSTS lists botulinum toxin as an option with moderate confidence from AAN-reviewed evidence; typically used selectively for focal symptoms rather than generalized tic burden (roessner2022europeanclinicalguidelines pages 1-2, monfrini2025frompharmacologicaltreatment pages 1-2)	Local weakness, site-specific adverse effects, need for repeat injections; best for carefully selected focal tics (monfrini2025frompharmacologicaltreatment pages 1-2, roessner2022europeanclinicalguidelines pages 1-2)	ESSTS pharmacologic guideline: https://doi.org/10.1007/s00787-021-01899-z (2022)
Cannabis-based medicines (e.g., THC-containing formulations, nabiximols)	Cannabinoid-system modulation	Considered in selected, treatment-resistant cases; evidence remains limited and sample sizes are small	Meta-analysis: YGTSS tic severity MD -13.88 (95% CI -23.07 to -4.68; P=0.003); YGTSS impairment MD -18.71 (95% CI -28.21 to -9.21; P<0.001); PUTS MD -5.36 (95% CI -8.46 to -2.27; P=0.0007); Y-BOCS change not significant (MD -6.22, P=0.06) (serag2024efficacyofcannabisbased pages 4-5)	Limited evidence base, small trials, heterogeneity; monitor cognitive/psychiatric adverse effects, sedation, and legal/regulatory issues; not a routine first-line therapy (serag2024efficacyofcannabisbased pages 4-5, monfrini2025frompharmacologicaltreatment pages 1-2)	Cannabis meta-analysis: https://doi.org/10.1007/s00228-024-03710-9 (2024)
Deep brain stimulation (DBS)	Neuromodulation of tic-related circuits; experimental/off-label surgical therapy for refractory disease	Reserved for carefully selected, severely affected, treatment-resistant patients after failure of behavioral and pharmacologic approaches	102-case multicenter cohort: YGTSS total improved 45.2% at 6 months, 51.6% at 12 months, 55.5% at 24 months, 55.6% at 36 months, 57.8% at 48 months, 61.4% at ≥60 months; children had greater ≥60-month improvement (70.1% vs 55.9% adults) and faster time to 60% improvement (6 vs 12 months); QoL and OCD/depression scores also improved (monfrini2025frompharmacologicaltreatment pages 12-14, mullervahl2022europeanclinicalguidelines media b45307e9)	ESSTS considers DBS experimental; requires multidisciplinary expert center, careful patient selection, programming follow-up, and monitoring for device/procedure-related complications and psychiatric effects (monfrini2025frompharmacologicaltreatment pages 12-14, mullervahl2022europeanclinicalguidelines pages 3-4)	Cohort study: https://doi.org/10.1186/s12916-024-03432-w (2024); ESSTS DBS guideline: https://doi.org/10.1007/s00787-021-01881-9 (2022)
Emerging D1/VMAT2 strategies: ecopipam, valbenazine, deutetrabenazine	Ecopipam: selective D1 antagonist; valbenazine/deutetrabenazine: VMAT2 inhibitors	Investigational / emerging options for Tourette syndrome; not established first-line care	Ecopipam has completed pediatric Phase 2b and Phase 3 programs, including randomized-withdrawal design in ages ≥6 years (NCT04007991; NCT05615220) (NCT04007991 chunk 1, NCT05615220 chunk 1). Valbenazine pediatric rollover was terminated after main study failed its primary endpoint, with no safety signal noted (NCT03732534 chunk 1). Deutetrabenazine pediatric RCT program completed but ESSTS summary notes deutetrabenazine failed primary endpoints in newer trials (mullervahl2022europeanclinicalguidelines pages 3-4, NCT02674321 chunk 1, NCT03452943 chunk 3)	Monitor agent-specific psychiatric, sleep/sedation, and movement-disorder adverse effects; these remain investigational or unsupported for routine use in Tourette syndrome at present (mullervahl2022europeanclinicalguidelines pages 3-4, NCT03732534 chunk 1, NCT02674321 chunk 1)	ClinicalTrials.gov: NCT04007991 (2019), NCT05615220 (2023), NCT03732534 (2018), NCT02674321 (2014)

Table: This table summarizes the main evidence-based Tourette syndrome treatments across behavioral, pharmacologic, cannabinoid, DBS, and emerging investigational approaches. It highlights practical use-cases, quantitative outcomes, and key monitoring issues with supporting context IDs and source URLs.

Key points: - First-line: psychoeducation and behavioral therapy (HRT/CBIT; ERP also recommended). (mullervahl2022europeanclinicalguidelines pages 1-3) - Medication when needed: ESSTS emphasizes dopamine-blocking agents (aripiprazole favored for adverse-event profile), plus alpha-2 agonists for coexisting ADHD. (roessner2022europeanclinicalguidelines pages 1-2) - Telehealth: videoconference/internet-delivered interventions show clinically meaningful reductions in tic severity and can improve access. (xu2025efficacyoftherapistsupported pages 5-6, amico2024efficacyofnonpharmacological pages 6-8) - DBS: reserved for carefully selected, refractory cases; long-term multicenter outcomes show sustained YGTSS improvement over years. (monfrini2025frompharmacologicaltreatment pages 12-14)

12.3 Emerging therapies and clinical trials (ClinicalTrials.gov)

Selected trials identified in the retrieved corpus: - Ecopipam (D1 antagonist) - Phase 2b pediatric RCT (NCT04007991; start 2019-06-28; completed 2021-09-23; ages ≥6 to <18; n=153; primary endpoint YGTSS-TTS change at Week 12). (NCT04007991 chunk 1) - Phase 3 randomized-withdrawal design (NCT05615220; start 2023-01-31; completed 2025-02-04; ages ≥6; n=216; primary endpoint time-to-relapse based on YGTSS criteria). (NCT05615220 chunk 1) - Valbenazine (VMAT2 inhibitor; NBI-98854) - Open-label Phase 2 safety/tolerability study (NCT02879578; started 2016-07-25; completed 2017-11-01; n=155; pediatric/adolescent/adult dosing strata; primary outcome TEAEs). (NCT02879578 chunk 1) - Pediatric rollover open-label Phase 2 (NCT03732534; ages 6–18; n=6; terminated after main study failed primary endpoint; “no safety concerns identified”). (NCT03732534 chunk 1) - Deutetrabenazine (VMAT2 inhibitor; SD-809) - Pilot Phase 1 open-label (NCT02674321; adolescents 12–18; n=23; completed; primary outcome safety/AEs; secondary outcomes include YGTSS changes). (NCT02674321 chunk 1)

MAXO suggestions (treatment action ontology; verify IDs): - Behavioral therapy / habit reversal training / exposure and response prevention (CBIT/HRT/ERP) (amico2024efficacyofnonpharmacological pages 3-5) - Antipsychotic therapy (aripiprazole/tiapride/risperidone) (roessner2022europeanclinicalguidelines pages 1-2) - Alpha-2 agonist therapy (clonidine/guanfacine) (roessner2022europeanclinicalguidelines pages 1-2) - Botulinum toxin injection (roessner2022europeanclinicalguidelines pages 1-2) - Deep brain stimulation (monfrini2025frompharmacologicaltreatment pages 12-14)

13. Prevention

No established primary prevention strategies were identified in the retrieved sources. Secondary/tertiary prevention focuses on early recognition, differential diagnosis (including functional tic-like presentations), and early access to behavioral therapy to reduce impairment. (szejko2022europeanclinicalguidelines pages 6-8, mullervahl2022europeanclinicalguidelines pages 1-3)

14. Other species / natural disease

No naturally occurring TS-equivalent disease in non-human species was identified in the retrieved evidence corpus.

15. Model organisms

The retrieved evidence contains limited direct model-organism characterization. A treatment review references histidine decarboxylase (HDC) gene relevance and an HDC knockout mouse model in the context of TS pathogenesis discussion. (jiao2024progressinthe pages 1-3)

Additional expert synthesis / interpretation (authoritative sources)

The ESSTS guideline update highlights a field-wide shift toward non-pharmacological interventions and shared decision-making, reflecting both evidence accumulation and patient-centered care priorities. (mullervahl2022europeanclinicalguidelines pages 1-3, mullervahl2022europeanclinicalguidelines media b45307e9)
The epidemiology review emphasizes that prevalence estimates vary widely due to ascertainment and diagnostic practices, implying that knowledge-base prevalence fields should record data provenance (survey-based vs clinician-assessed cohorts). (yilmaz2025epidemiologyoftourette pages 1-4, xiong2024prevalenceoftourette pages 1-2)

Key references (URLs in-line; publication year)

Xiong et al. BMC Public Health (2024-10): NSCH prevalence 2016–2022. https://doi.org/10.1186/s12889-024-20216-2 (xiong2024prevalenceoftourette pages 1-2)
Jiang et al. Frontiers in Neurology (2024-02): biomarker meta-analysis; no gold-standard test. https://doi.org/10.3389/fneur.2024.1262057 (jiang2024biomarkersandtourette pages 1-2)
Fichna et al. Int J Mol Sci (2024-05): familial WGS structural variants and enriched processes. https://doi.org/10.3390/ijms25115758 (fichna2024structuralvariantsand pages 1-2)
Abbasi et al. Italian Journal of Pediatrics (2023-12): depression/anxiety prevalence meta-analysis. https://doi.org/10.1186/s13052-023-01562-0 (abbasi2023prevalenceofdepression pages 1-2)
ESSTS guidelines v2.0 (2022): assessment (Part I), psychological (Part II), pharmacology (Part III), DBS (Part IV). https://doi.org/10.1007/s00787-021-01842-2; https://doi.org/10.1007/s00787-021-01845-z; https://doi.org/10.1007/s00787-021-01899-z; https://doi.org/10.1007/s00787-021-01881-9 (szejko2022europeanclinicalguidelines pages 11-12, szejko2022europeanclinicalguidelines pages 6-8, roessner2022europeanclinicalguidelines pages 1-2, monfrini2025frompharmacologicaltreatment pages 12-14)

References

(abbasi2023prevalenceofdepression pages 1-2): Parvin Abbasi, Sepideh Tanhaie, and Mohsen Kazeminia. Prevalence of depression and anxiety in patients with tourette syndrome; 1997 to 2022: a systematic review and meta-analysis. Italian Journal of Pediatrics, Dec 2023. URL: https://doi.org/10.1186/s13052-023-01562-0, doi:10.1186/s13052-023-01562-0. This article has 20 citations and is from a peer-reviewed journal.
(jiang2024biomarkersandtourette pages 1-2): Yanlin Jiang, Yuan Li, Xi Chen, Rui Zhai, Yaqi Peng, Ran Tai, Congxiao Zhou, and Junhong Wang. Biomarkers and tourette syndrome: a systematic review and meta-analysis. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1262057, doi:10.3389/fneur.2024.1262057. This article has 12 citations and is from a peer-reviewed journal.
(xiong2024prevalenceoftourette pages 1-2): Yuhong Xiong, Matthew O’Brien, Wenhan Yang, Xiaodong Zang, Wei Bao, and Guifeng Xu. Prevalence of tourette syndrome among children and adolescents in the united states, 2016–2022. BMC Public Health, Oct 2024. URL: https://doi.org/10.1186/s12889-024-20216-2, doi:10.1186/s12889-024-20216-2. This article has 14 citations and is from a peer-reviewed journal.
(szejko2022europeanclinicalguidelines pages 1-2): Natalia Szejko, Sally Robinson, Andreas Hartmann, Christos Ganos, Nanette M. Debes, Liselotte Skov, Martina Haas, Renata Rizzo, Jeremy Stern, Alexander Münchau, Virginie Czernecki, Andrea Dietrich, Tara L. Murphy, Davide Martino, Zsanett Tarnok, Tammy Hedderly, Kirsten R. Müller-Vahl, and Danielle C. Cath. European clinical guidelines for tourette syndrome and other tic disorders—version 2.0. part i: assessment. European Child & Adolescent Psychiatry, 31:383-402, Oct 2022. URL: https://doi.org/10.1007/s00787-021-01842-2, doi:10.1007/s00787-021-01842-2. This article has 141 citations and is from a domain leading peer-reviewed journal.
(amico2024efficacyofnonpharmacological pages 1-2): Cecilia Amico, Chiara Crepaldi, Margherita Rinaldi, Elisa Buffone, Simona Scaini, Barbara Forresi, and Mauro Leoni. Efficacy of nonpharmacological treatment in children and adolescent with tic disorder: a systematic review. Applied Sciences, 14:9466, Oct 2024. URL: https://doi.org/10.3390/app14209466, doi:10.3390/app14209466. This article has 1 citations.
(szejko2022europeanclinicalguidelines pages 6-8): Natalia Szejko, Sally Robinson, Andreas Hartmann, Christos Ganos, Nanette M. Debes, Liselotte Skov, Martina Haas, Renata Rizzo, Jeremy Stern, Alexander Münchau, Virginie Czernecki, Andrea Dietrich, Tara L. Murphy, Davide Martino, Zsanett Tarnok, Tammy Hedderly, Kirsten R. Müller-Vahl, and Danielle C. Cath. European clinical guidelines for tourette syndrome and other tic disorders—version 2.0. part i: assessment. European Child & Adolescent Psychiatry, 31:383-402, Oct 2022. URL: https://doi.org/10.1007/s00787-021-01842-2, doi:10.1007/s00787-021-01842-2. This article has 141 citations and is from a domain leading peer-reviewed journal.
(fichna2024structuralvariantsand pages 1-2): Jakub P. Fichna, Mateusz Chiliński, Anup Kumar Halder, Paweł Cięszczyk, Dariusz Plewczynski, Cezary Żekanowski, and Piotr Janik. Structural variants and implicated processes associated with familial tourette syndrome. International Journal of Molecular Sciences, 25:5758, May 2024. URL: https://doi.org/10.3390/ijms25115758, doi:10.3390/ijms25115758. This article has 2 citations.
(mullervahl2022europeanclinicalguidelines pages 3-4): Kirsten R. Müller-Vahl, Natalia Szejko, Cara Verdellen, Veit Roessner, Pieter J. Hoekstra, Andreas Hartmann, and Danielle C. Cath. European clinical guidelines for tourette syndrome and other tic disorders: summary statement. European Child & Adolescent Psychiatry, 31:377-382, Jul 2022. URL: https://doi.org/10.1007/s00787-021-01832-4, doi:10.1007/s00787-021-01832-4. This article has 99 citations and is from a domain leading peer-reviewed journal.
(yilmaz2025epidemiologyoftourette pages 1-4): Abdullah Yasir Yilmaz and Joseph Jankovic. Epidemiology of tourette syndrome. Brain Sciences, 15:426, Apr 2025. URL: https://doi.org/10.3390/brainsci15050426, doi:10.3390/brainsci15050426. This article has 12 citations.
(strom2025geneticriskof pages 73-75): NI Strom. Genetic risk of obsessive-compulsive disorder and related psychiatric phenotypes-insights from large-scale genome-wide association studies. Unknown journal, 2025.
(fichna2024structuralvariantsand pages 4-5): Jakub P. Fichna, Mateusz Chiliński, Anup Kumar Halder, Paweł Cięszczyk, Dariusz Plewczynski, Cezary Żekanowski, and Piotr Janik. Structural variants and implicated processes associated with familial tourette syndrome. International Journal of Molecular Sciences, 25:5758, May 2024. URL: https://doi.org/10.3390/ijms25115758, doi:10.3390/ijms25115758. This article has 2 citations.
(dalsberg2026transcriptomeandepigenomewide pages 1-2): Jonas Dalsberg, Cathrine Jespersgaard, Amanda M. Levy, Anna Maria Asplund, Frederik Otzen Bagger, Nanette M. Debes, Qihua Tan, Zeynep Tümer, and Mathis Hildonen. Transcriptome- and epigenome-wide association studies of tic spectrum disorder in discordant monozygotic twins. Genes, 17:97, Jan 2026. URL: https://doi.org/10.3390/genes17010097, doi:10.3390/genes17010097. This article has 0 citations.
(szejko2022europeanclinicalguidelines pages 11-12): Natalia Szejko, Sally Robinson, Andreas Hartmann, Christos Ganos, Nanette M. Debes, Liselotte Skov, Martina Haas, Renata Rizzo, Jeremy Stern, Alexander Münchau, Virginie Czernecki, Andrea Dietrich, Tara L. Murphy, Davide Martino, Zsanett Tarnok, Tammy Hedderly, Kirsten R. Müller-Vahl, and Danielle C. Cath. European clinical guidelines for tourette syndrome and other tic disorders—version 2.0. part i: assessment. European Child & Adolescent Psychiatry, 31:383-402, Oct 2022. URL: https://doi.org/10.1007/s00787-021-01842-2, doi:10.1007/s00787-021-01842-2. This article has 141 citations and is from a domain leading peer-reviewed journal.
(yilmaz2025epidemiologyoftourette pages 9-11): Abdullah Yasir Yilmaz and Joseph Jankovic. Epidemiology of tourette syndrome. Brain Sciences, 15:426, Apr 2025. URL: https://doi.org/10.3390/brainsci15050426, doi:10.3390/brainsci15050426. This article has 12 citations.
(yilmaz2025epidemiologyoftourette pages 8-9): Abdullah Yasir Yilmaz and Joseph Jankovic. Epidemiology of tourette syndrome. Brain Sciences, 15:426, Apr 2025. URL: https://doi.org/10.3390/brainsci15050426, doi:10.3390/brainsci15050426. This article has 12 citations.
(serag2024efficacyofcannabisbased pages 4-5): Ibrahim Serag, Mona Mahmoud Elsakka, Mostafa Hossam El din Moawad, Hossam Tharwat Ali, Khalid Sarhan, Sally Shayeb, Islam Nadim, and Mohamed Abouzid. Efficacy of cannabis-based medicine in the treatment of tourette syndrome: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 80:1483-1493, Jul 2024. URL: https://doi.org/10.1007/s00228-024-03710-9, doi:10.1007/s00228-024-03710-9. This article has 10 citations and is from a peer-reviewed journal.
(mullervahl2022europeanclinicalguidelines media b45307e9): Kirsten R. Müller-Vahl, Natalia Szejko, Cara Verdellen, Veit Roessner, Pieter J. Hoekstra, Andreas Hartmann, and Danielle C. Cath. European clinical guidelines for tourette syndrome and other tic disorders: summary statement. European Child & Adolescent Psychiatry, 31:377-382, Jul 2022. URL: https://doi.org/10.1007/s00787-021-01832-4, doi:10.1007/s00787-021-01832-4. This article has 99 citations and is from a domain leading peer-reviewed journal.
(amico2024efficacyofnonpharmacological pages 3-5): Cecilia Amico, Chiara Crepaldi, Margherita Rinaldi, Elisa Buffone, Simona Scaini, Barbara Forresi, and Mauro Leoni. Efficacy of nonpharmacological treatment in children and adolescent with tic disorder: a systematic review. Applied Sciences, 14:9466, Oct 2024. URL: https://doi.org/10.3390/app14209466, doi:10.3390/app14209466. This article has 1 citations.
(amico2024efficacyofnonpharmacological pages 5-6): Cecilia Amico, Chiara Crepaldi, Margherita Rinaldi, Elisa Buffone, Simona Scaini, Barbara Forresi, and Mauro Leoni. Efficacy of nonpharmacological treatment in children and adolescent with tic disorder: a systematic review. Applied Sciences, 14:9466, Oct 2024. URL: https://doi.org/10.3390/app14209466, doi:10.3390/app14209466. This article has 1 citations.
(amico2024efficacyofnonpharmacological pages 6-8): Cecilia Amico, Chiara Crepaldi, Margherita Rinaldi, Elisa Buffone, Simona Scaini, Barbara Forresi, and Mauro Leoni. Efficacy of nonpharmacological treatment in children and adolescent with tic disorder: a systematic review. Applied Sciences, 14:9466, Oct 2024. URL: https://doi.org/10.3390/app14209466, doi:10.3390/app14209466. This article has 1 citations.
(mullervahl2022europeanclinicalguidelines pages 1-3): Kirsten R. Müller-Vahl, Natalia Szejko, Cara Verdellen, Veit Roessner, Pieter J. Hoekstra, Andreas Hartmann, and Danielle C. Cath. European clinical guidelines for tourette syndrome and other tic disorders: summary statement. European Child & Adolescent Psychiatry, 31:377-382, Jul 2022. URL: https://doi.org/10.1007/s00787-021-01832-4, doi:10.1007/s00787-021-01832-4. This article has 99 citations and is from a domain leading peer-reviewed journal.
(xu2025efficacyoftherapistsupported pages 5-6): Xiaolei Xu, Kangsheng Zhu, Weiyi Wang, Tianyu Zhao, and Congrui Fu. Efficacy of therapist-supported online remote behavioral therapy for tic disorders: a systematic review and meta-analysis. Frontiers in Psychiatry, Jun 2025. URL: https://doi.org/10.3389/fpsyt.2025.1521947, doi:10.3389/fpsyt.2025.1521947. This article has 0 citations.
(roessner2022europeanclinicalguidelines pages 1-2): Veit Roessner, Heike Eichele, Jeremy S. Stern, Liselotte Skov, Renata Rizzo, Nanette Mol Debes, Péter Nagy, Andrea E. Cavanna, Cristiano Termine, Christos Ganos, Alexander Münchau, Natalia Szejko, Danielle Cath, Kirsten R. Müller-Vahl, Cara Verdellen, Andreas Hartmann, Aribert Rothenberger, Pieter J. Hoekstra, and Kerstin J. Plessen. European clinical guidelines for tourette syndrome and other tic disorders—version 2.0. part iii: pharmacological treatment. European Child & Adolescent Psychiatry, 31:425-441, Nov 2022. URL: https://doi.org/10.1007/s00787-021-01899-z, doi:10.1007/s00787-021-01899-z. This article has 202 citations and is from a domain leading peer-reviewed journal.
(roessner2022europeanclinicalguidelines pages 8-9): Veit Roessner, Heike Eichele, Jeremy S. Stern, Liselotte Skov, Renata Rizzo, Nanette Mol Debes, Péter Nagy, Andrea E. Cavanna, Cristiano Termine, Christos Ganos, Alexander Münchau, Natalia Szejko, Danielle Cath, Kirsten R. Müller-Vahl, Cara Verdellen, Andreas Hartmann, Aribert Rothenberger, Pieter J. Hoekstra, and Kerstin J. Plessen. European clinical guidelines for tourette syndrome and other tic disorders—version 2.0. part iii: pharmacological treatment. European Child & Adolescent Psychiatry, 31:425-441, Nov 2022. URL: https://doi.org/10.1007/s00787-021-01899-z, doi:10.1007/s00787-021-01899-z. This article has 202 citations and is from a domain leading peer-reviewed journal.
(monfrini2025frompharmacologicaltreatment pages 1-2): E. Monfrini, Christian Saleh, D. Servello, Phillip Jaszczuk, M. Porta, Noriyuki Koibuchi, and V. Lessmann. From pharmacological treatment to neuromodulation: a comprehensive approach to managing gilles de la tourette syndrome. International Journal of Molecular Sciences, 26:8831, Sep 2025. URL: https://doi.org/10.3390/ijms26188831, doi:10.3390/ijms26188831. This article has 0 citations.
(monfrini2025frompharmacologicaltreatment pages 12-14): E. Monfrini, Christian Saleh, D. Servello, Phillip Jaszczuk, M. Porta, Noriyuki Koibuchi, and V. Lessmann. From pharmacological treatment to neuromodulation: a comprehensive approach to managing gilles de la tourette syndrome. International Journal of Molecular Sciences, 26:8831, Sep 2025. URL: https://doi.org/10.3390/ijms26188831, doi:10.3390/ijms26188831. This article has 0 citations.
(NCT04007991 chunk 1): Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents. Emalex Biosciences Inc.. 2019. ClinicalTrials.gov Identifier: NCT04007991
(NCT05615220 chunk 1): Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults. Emalex Biosciences Inc.. 2023. ClinicalTrials.gov Identifier: NCT05615220
(NCT03732534 chunk 1): Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome. Neurocrine Biosciences. 2018. ClinicalTrials.gov Identifier: NCT03732534
(NCT02674321 chunk 1): A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS). Auspex Pharmaceuticals, Inc.. 2014. ClinicalTrials.gov Identifier: NCT02674321
(NCT03452943 chunk 3): Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents. Teva Branded Pharmaceutical Products R&D, Inc.. 2018. ClinicalTrials.gov Identifier: NCT03452943
(NCT02879578 chunk 1): Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome. Neurocrine Biosciences. 2016. ClinicalTrials.gov Identifier: NCT02879578
(jiao2024progressinthe pages 1-3): Wenyan Jiao, Muhammetaly Agamedov, Guvanch D. Kerimov, Jia-Wei Zheng, Stefan Bittmann, Begench Annaye, and Fuyong Jiao. Progress in the treatment of tourette syndrome. Asian Journal of Pediatric Research, 14:39-45, Oct 2024. URL: https://doi.org/10.9734/ajpr/2024/v14i10395, doi:10.9734/ajpr/2024/v14i10395. This article has 0 citations.

Ask OpenScientist

OpenScientist Report

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Differential Diagnoses

Related Datasets

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Tourette Syndrome (TS) — Disease Characteristics Research Report

0. Executive summary

1. Disease information

1.1 Disease overview (current understanding)

1.2 Synonyms / alternative names

1.3 Key identifiers (ontology / coding)

2. Etiology

2.1 Causal factors (genetic, environmental, mechanistic)

2.2 Risk factors

Genetic risk factors

Environmental / psychosocial risk factors

2.3 Protective factors

2.4 Gene–environment interaction

3. Phenotypes

3.1 Core phenotypes and HPO mapping (suggested)

3.2 Phenotype characteristics (onset, severity, course, frequency)

3.3 Quality-of-life impact

3.4 Psychiatric comorbidity burden (statistics)

4. Genetic / molecular information

4.1 Causal genes and pathogenic variants

4.2 Structural variants and implicated genes (2024 study)

4.3 Polygenic risk and implicated loci (recent large-scale genetics)

4.4 Pathway/process annotations (GO/Reactome/KEGG suggestions)

5. Environmental information

6. Mechanism / pathophysiology

6.1 Circuit-level mechanisms (current consensus)

6.2 Neuroimmune and peripheral biomarker findings (2024)

6.3 Proposed causal chain (integrated, evidence-aligned)

6.4 Cell types and CL term suggestions

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

9.1 Epidemiology (recent and quantitative)

9.2 Sex ratio

10. Diagnostics

10.1 Clinical criteria and assessment approach

10.2 Rating scales (ESSTS 2022)

10.3 Differential diagnosis (including functional tic-like behaviors)

11. Outcome / prognosis

12. Treatment

12.1 Guideline-based treatment algorithm (ESSTS)

12.2 Evidence-based interventions and real-world implementation

12.3 Emerging therapies and clinical trials (ClinicalTrials.gov)

13. Prevention

14. Other species / natural disease

15. Model organisms

Additional expert synthesis / interpretation (authoritative sources)